Valparaiso University

ValpoScholar
Evidence-Based Practice Project Reports

College of Nursing and Health Professions

4-26-2018

A Multi-faceted Intervention to Improve Naloxone
Co-Prescription Rates Among Primary Care
Providers
Jolane S. Conklin
Vaparaiso University, jolane.conklin@valpo.edu

Follow this and additional works at: https://scholar.valpo.edu/ebpr
Part of the Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons,
Health and Medical Administration Commons, Nursing Commons, Primary Care Commons, Public
Health Commons, and the Substance Abuse and Addiction Commons

Recommended Citation
Conklin, Jolane S., "A Multi-faceted Intervention to Improve Naloxone Co-Prescription Rates Among Primary Care Providers"
(2018). Evidence-Based Practice Project Reports. 112.
https://scholar.valpo.edu/ebpr/112

This Evidence-Based Project Report is brought to you for free and open access by the College of Nursing and Health Professions at ValpoScholar. It has
been accepted for inclusion in Evidence-Based Practice Project Reports by an authorized administrator of ValpoScholar. For more information, please
contact a ValpoScholar staff member at scholar@valpo.edu.

ii

Copyright © 2018 by Jolane S. Conklin

This work is licensed under a
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

iii

DEDICATION
This project is dedicated to family: my husband, Dan; my children, Zack and Kayla; and my
parents, Roy and Alana. The journey to get to this point has been arduous, and each one of
you has made sacrifices to ensure I accomplished my goals. Thank you for sharing the burden
and supporting me during my educational endeavors – we made it happen!

“Dripping water hollows out stone, not through force but through persistence. “
- Ovid

iv

ACKNOWLEDGMENTS
I would like to acknowledge and thank Dr. Julie Koch for her unwavering support, patience, and
wisdom throughout the course of this project. Without her, I’m sure this project would have
“derailed” several times. Her commitment to her students is exemplary and does not go
unnoticed.
I would also like to thank Nicole Edson, who began her nursing career with me many years ago
and has found herself as my clinical manager. With her support, along with that of our health
director (Rosalind Johnston), and our fellow colleagues, this project and my educational goals
were seen to fruition. It truly would not have been possible without each of you.

v

PREFACE
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Regarding opioid prescribing and efforts to combat the opioid epidemic
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ABSTRACT
A Multi-Faceted Intervention to Improve Naloxone Co-Prescription Rates
Among Primary Care Providers
Jolane S. Conklin, MSN, APRN, FNP-C, ADS
It is estimated that 91 Americans die every day due to opioid overdoses, with at least half of
those overdoses involving an opioid prescription (CDC, 2016d). To address this issue, the U.S.
Department of Health and Human Services (USDHHS) has initiated an opioid initiative, and the
Centers for Disease Control and Prevention (CDC) has released a clinical guideline, both of
which include a focus on increasing use of naloxone. Despite these recommendations,
providers often fail to co-prescribe naloxone to patients at increased risk of opioid overdose.
The purpose of this evidence-based practice (EBP) project was to evaluate the effect of a multifaceted intervention (including the use of academic detailing sessions, provider reminders, and
a clinical champion) to increase naloxone co-prescription rates within an Indian Health Services
Tribal Health Department in the Midwestern United States. The Iowa Model of Evidence-based
Practice and Kotter’s Change Model were used to guide this project, which was supported by 10
pieces of evidence obtained through a systematic search of the literature. Retrospective chart
audits were conducted on patients receiving opioid prescriptions of 30 days or greater during
the 12-week intervention period and the same time period in 2016. Descriptive statistics were
used to compare the frequency of naloxone co-prescriptions pre-intervention (0 of 48 eligible
patients; 0%) and post-intervention (10 of 40 eligible patients; 25%). The 25-percentage point
increase in co-prescribing was consistent with the supportive evidence and reflected a
statistically significant association between the multi-faceted intervention and naloxone coprescription distribution (X2 = 13.538, p <.001). Of the secondary variables of interest, only
patient gender was associated with naloxone to a statistically significant level. Results of this
EBP project lend support to the recommendation of use of this multifaceted approach as a
strategy to increase naloxone co-prescription rates among primary care providers.

xi
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CHAPTER 1
INTRODUCTION
Background
The first reference to opioids in our society has been reported to date back to Sumerian
culture more than 6000 years ago, when it was noted that cultivation of poppy was the “plant of
happiness” (Green, 2017). Throughout the course of history, opioids have taken many names,
including laudanum that was used in North America and Europe until the start of the twentieth
century (Green, 2017). By the year 1805, opioids began to be known by a name familiar to
most in present day: morphine. It was at this point that the active component of opium was
discovered and named Morpheus, in honor of the Greek god of dreams (Green, 2017). Now,
opioids are present in many formulations and strengths due to advances in pharmaceutical
synthetic manufacturing (see Table 1.1 Common Opioids).
Opioids affect the central nervous system by binding with mu receptors, which
regulate pain and addiction centers within the brain. As the opioids bind to the receptors,
physiological responses occur including pain relief, decreased respirations, mood changes,
pupil constriction, decreased gastrointestinal tract activity, and stimulation of the receptors that
control nausea and vomiting (Calas, Wilkin, & Oliphant, 2016). An overdose of opioids can lead
to significant depression of the respiratory center, thus causing cessation of spontaneous
respiration which leads to death.
It has been noted that those at higher risk for prescription opioid overdose may include
those who are taking higher doses of opioids and those who misuse (skip doses on “good” pain
days and double up doses on “bad” pain days), inject, or take in combination with other
substances that cause respiratory depression (e.g., benzodiazepines or alcohol) (Calas et al.,
2016; Dowell, Hagerich, & Chou, 2016; Duvivier et al., 2017). Additionally, those who have
other co-morbidities (e.g., advanced age, depression, lung disease, or liver disease) and those
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who have recently had a period of abstinence from opioid use stemming from recent
incarceration or rehabilitation may also be at higher risk (Calas et al., 2016; Dowell et al., 2016;
Duvivier et al., 2017). Individuals who have difficulty accessing care due to remote locations,
lack of transportation, homelessness, or without access to phone services are also considered
high risk for opioid overdose (Calas et al., 2016; Dowell et al., 2016; Duvivier et al., 2017).
Naloxone, a medication developed in 1971 as a prescription formulation, and until
recently used primarily in hospital settings, is an opioid antagonist that works by binding with the
mu receptors in the brain (Calas et al., 2016; Jacobs, 2016). In doing such, opioids are
displaced from the mu receptors, thus reversing the effects of central nervous system
depression, effectively reversing the physiological symptoms of an opioid overdose; but,
naloxone has a half-life of only approximately 30 to 90 minutes, so as the effects wear off,
opioids that remain circulating in the blood will again bind to the mu receptors (Calas et al.,
2016). Although naloxone’s short half-life only buys an opioid overdose victim time for further
intervention, it does allow a window of opportunity to access higher level care services. Unique
to naloxone, due to its mechanism of action, are no adverse effects to those individuals who
would happen to receive a dose in the absence of a true opioid overdose situation (Calas et al.,
2016; Duvivier et al., 2017). This potentially life-saving medication has been named as a
component in various opioid initiatives, with a push to expand access of naloxone to lay-users
who may be at risk for opioid overdose themselves or have known family and friends who may
be at risk for opioid overdose (Calas et al., 2016; Centers for Disease Control and Prevention
[CDC], 2016a; Duvivier et al., 2017; Mueller, Walley, Calcaterra, Glanz, & Binswanger, 2015).
Statement of the Problem
Data from the Literature Supporting Need for the Project
As unintended overdoses from opioid drugs continue to climb in the United States (U.S.),
community members, health care professionals, and government agencies are searching
intensely for solutions to combat the escalating epidemic. Those who suffer from addiction and
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those that have the potential for overdose due to legally prescribed and obtained medications,
as well as their families, are demanding that something be done.
The CDC (2016c) has reported that opioids were involved in 28,647 deaths (61% of all
drug overdose deaths) in the U.S. in 2014 and that opioid overdoses have quadrupled since
1999. During this same timeframe, the number of prescriptions written for opioid medications
also quadrupled, despite no increased reports of the level of pain in Americans (CDC, 2016c).
Additionally, it is estimated that 91 people in the U.S. die every day due to opioid overdoses,
with at least half of those overdoses involving an opioid prescription (CDC, 2016d).
Furthermore, 1,000 people are treated every day in emergency departments across the country
for conditions related to not using opioid prescriptions as directed (CDC, 2016c).
The State of Michigan saw a statistically significant increase in opioid death rates
(13.3%) between 2014 and 2015 and had one of the highest overdose death rates in the nation:
20.4 per 100,000 population (CDC, 2016b). In 2015, drug overdose was the leading cause of
injury death in Michigan, outpacing motor vehicle accidents, firearm discharge, and suicide
(CDC, 2016d). Furthermore, not only has geographic focus been a concern, but so has the
status of populations that historically have been known to be at higher risk: Native Americans.
Drug-related deaths among Native American Indians and Alaskan Natives increased from 5 per
100,000 population between 1989-1991 to 22.7 per 100,000 population between 2007 and 2009
(Indian Health Services [IHS], 2015). The rate of drug-related deaths among Native Americans
was almost twice that of all races in the same time frame (IHS, 2015), and in 2015, unintentional
poisoning (drug overdose), was the leading cause of injury death among Native Americans in
Michigan (CDC, 2016d).
Prescription opioids, while initially utilized for legitimate purposes, have been shown to
lead to higher rates of opioid usage. A recent study found that even one prescription for opioids
can be a trigger for abuse (Shah, Hayes, & Martin, 2017). Additionally, the risk of long term
opioid use increases sharply when patients are given (a) a long-acting opioid, (b) a 10- to 30-
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day supply, (c) more than 700 morphine milligrams cumulative dose, or (d) if they return for a
second prescription or refill (Shah et al., 2017).
Recognizing that prescription opioid use has the potential for overdose and can be
viewed as a gateway to illicit drug use, both of which have reached epidemic levels, in March
2015, the U.S. Department of Health and Human Services (USDHHS) released their opioid
initiative, which highlights three priority areas of focus to address opioid drug and heroin
overdose and death: (a) provide training and education resources, (b) increase use of naloxone,
and (c) expand the use of medication-assisted treatment (USDHHS, 2016). Following that
national initiative, in March 2016, the CDC released a clinical guideline for prescribing opioids
for chronic pain to combat the present epidemic (CDC, 2016a). The guideline contains 12
recommendations regarding safe opioid prescribing. Among these, a focus on assessing risk
and addressing harms of opioid use exists, namely offering co-prescriptions of naloxone when
prescribing opioids to patients at increased risk of overdose (CDC, 2016a).
Data from the Clinical Agency Supporting Need for the Project
Located in Southwest Michigan, the clinical agency was part of a rural tribal health
department located on reservation land and partially funded by Indian Health Services (IHS).
Facilities also included two other satellite locations, one in an urban area and one located inside
a nearby occupational setting. These clinics provide primary care services, dental services,
social and behavioral health services, nutrition services, and community health services to all
federally recognized tribal members, their family members, and the employees of the
organization. As much as possible, all three clinics attempt to provide comparable services and
abide by the same policies and procedures.
A recently completed health needs survey of area tribal members confirmed concerns
previously identified by health care providers in the clinic:11.9% of tribal members surveyed
reported using a prescription drug for experience (i.e., the feeling it caused or to get high), well
above the 4.7% average lifetime prevalence of all races (Great Lakes Inter-Tribal Epidemiology
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Center, 2016). Additionally, 3.97% of those surveyed reported misuse of prescription drugs
within the past 30 days (Great Lakes Inter-Tribal Epidemiology Center, 2016). Furthermore, in
reviewing adverse childhood experiences (ACEs), which have been shown to correlate with
increased risk of opioid misuse, 24.23% of those surveyed reported living with a problem drinker
or alcoholic before the participant turned 18, and 11.03% indicated the same circumstances
regarding living with someone who abused illegal street drugs or prescription drugs (Great
Lakes Inter-Tribal Epidemiology Center, 2016).
Both the current rates of misuse of prescription medications, as well as the reported
level of ACEs, confirmed the significance of the problem to the tribal health department staff,
specifically the prescribing providers. As a result, the prescribing providers felt compelled to
review previous polices regarding controlled substance prescribing.
The clinical agency did have an existing policy that was developed prior to the
employment of the current providers and clinical manager, but the policy did not address several
present-day issues (i.e., recently published guidelines for safe prescribing, and inclusion of
prescription monitoring database programs). Discussions at group meetings between the
Doctor of Nursing Practice (DNP) student facilitator, the clinical manager, the medical director
(an internal medicine physician), two physician assistants (PAs), and one staff physician echoed
the same themes: (a) the current practice policy was outdated and needed to be reviewed, (b)
safe opioid prescribing practices needed to be addressed systematically, and (c) providers did
not feel well versed in current guidelines and were uncertain of how to adequately prevent
opioid overdose.
During this same timeframe, the local tribal government that provided clinic oversight,
expressed their concern in taking a proactive approach to opioid overdose prevention across all
tribal lands and properties; the organization implemented a naloxone distribution policy for those
at risk for overdose. The combination of provider discussions regarding outdated controlled
substance policies, tribal governmental policy changes, and national opioid prescribing guideline
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updates prompted Clinic X provider discussion regarding (a) the identification of those at risk for
opioid overdose and (b) the ability and appropriateness of prescribing naloxone for overdose
death prevention. The providers identified barriers to prescribing naloxone for current clinic
patients: proper identification of appropriate candidates, unfamiliarity with current guideline
recommendations of co-naloxone prescribing, patients not self-identifying as an overdose risk,
and general lack of knowledge regarding the technicalities of writing a naloxone prescription
(Clinic X Manager, personal communication, March 1, 2017). One provider anecdotally
reported having written a naloxone prescription only once, at the request of the family, while the
other providers reported having never written a naloxone prescription (Providers of Clinic X,
personal communication, March 1, 2017). Despite the lone provider’s indication of prescribing
naloxone, evaluation of eligible patients between September 25, 2016 through December 15,
2016, demonstrated 48 patients receiving chronic opioids prescriptions of 30 days or greater;
none of which received a naloxone co-prescription.
Purpose of the Evidence-Based Practice Project
Compelling Clinical Question
An agency and community-wide push to become proactive in opioid overdose prevention
demonstrate the need for a time-efficient, evidence-based practice (EBP) project which would
incorporate a thorough review of current practice standards and guidelines as well as aid in
identifying barriers and implementing strategies that would help improve naloxone coprescription rates among clinic patients who received chronic opioid prescriptions. Thus, the
development of the compelling clinical inquiry arose: What are the best strategies for improving
provider rates of naloxone co-prescriptions to those receiving chronic opioid medications in a
primary care setting?
PICOT Question
Melnyk and Fineout-Overhold (2011) have noted that once there is awareness of a
compelling clinical inquiry, then a clinical question can be developed. To guide the development
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of this project and facilitate the procurement of the best available evidence, the PICOT (patient
population, intervention of interest, comparison intervention or status, outcome and timeframe)
format was used. Utilizing this PICOT format led to the development of the question for this
project: (P) Among primary care providers in a tribal health clinic, (I) does the introduction of an
evidence- based multi-faceted intervention (C) versus the current practice of no tool, (O)
improve the co-prescription rates of naloxone to chronic opioid patients (T) within a 12- week
period?
Significance of the EBP Project
The goal of this EBP project was to improve naloxone co-prescription rates among clinic
providers for the purpose of taking a proactive approach to opioid overdose death prevention.
With the release of CDC guidelines in early 2016, providers were given guidance on safe
prescribing practices and recommendations which, in the midst of the opioid epidemic plaguing
not only the United States, but the world, were desperately needed (Dowell et al., 2016).
However, due to time gaps from publication to disseminating and implementing these guidelines
fully into today’s complicated primary care structure, the benchmark for the level of guideline
adherence had not been established.
As the opioid overdose crisis continues to morph, primary care clinicians are poised in a
pivotal juncture to both limit the opioids being prescribed and aid in the access to interventions
in the event of accidental or intentional overdoses. There is significant literature that indicates
primary care providers feel neither confident nor empowered to approach patients with the
pretense to simply discuss potential adverse outcomes of opioid substances, much less feel
comfortable to discuss naloxone co-prescriptions and actually dispense them (Binswanger et
al., 2015; Kerensky & Walley, 2017; Mueller et al., 2015; Wilson, Rodriguez, Carrington, &
Fagan, 2017). Although the opioid epidemic is far-reaching, and the answer does not lie with a
single intervention, providers must exercise caution in regard to opioid prescribing and their
duty, both ethically and legally, to prevent any unintended consequences. It is with that
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intention, that this EBP project was developed…with the altruistic goal of preventing the loss of
life by focusing on a single aspect of the battle: improvement of naloxone co-prescription rates
in the primary care setting.
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Table 1.1
Commonly Prescribed Opioids
Generic

Brand Name

Half-life (hours)

Buprenorphine

Buprenex, Butrans

24-60

Codeine

Capital/Codeine, Tylenol with

4

Codeine #3, Tylenol with
Codeine #4
Fentanyl

Abstral, Actiq, Duragesic,

2-4

Fentora, Lazanda,Lonsys,
Onsolis, Subsys
Hydrocodone

Lorcet, Lortab, Maxidone,

3-5

Norco, Reprexain, Stagesic,
Verdrocet, Vicodin,
Vicoprofen, Xodol, Xylon,
Zydonelbudone
Hydromorphone

Dilaudid

2-3

Meperidine

Demerol, Meperitab

2.5-4

Methadone

Dolophine, Methadose

8-59

Morphine

Astramorph, Duraporph,

2-4

Infumorph, MSContin
Oxycodone

Endocet, Endodan, Magnacet,

2-4

Percocet, Percodan, Primlev,
Roxicet, Roxicodone
Oxymorphone

Opana

Note: Adapted from Epocrates Plus, (2017).

7-9

NALOXONE CO-PRESCRIBING

10

CHAPTER 2
THEORETICAL FRAMEWORK, EBP MODEL, AND REVIEW OF LITERATURE
Theoretical Framework
Melnyk and Fineout-Overholt (2015) defined evidence-based practice (EBP) as “a
paradigm and lifelong problem-solving approach to clinical decision making that involves the
conscientious use of the best available evidence with one’s own clinical expertise and patient
values and preferences to improve outcomes for individuals, groups, communities and systems”
(p. 604). Implementing EBP into clinical practice can be challenging due any number of barriers
hindering the process. Therefore, utilizing a model to systematically guide the implementation
of EBP can be beneficial (Melnyk & Fineout-Overholt, 2015).
To facilitate the translation of evidence into clinical practice within this DNP project, the
Iowa Model of Evidence-Based practice was incorporated. The DNP student facilitator used the
Iowa Model to integrate current high-quality evidence into clinical practice, with consideration of
the targeted population’s clinical status and circumstances, their preferences and expertise,
available resources, and current beliefs. Aware of the importance for a systematic approach to
aid in successful implementation, the DNP student facilitator also incorporated Kotter’s Model of
Change as the theoretical framework to guide the change processes that were intended to
increase naloxone co-prescription rates among primary care providers in the project facility.
Overview of Theoretical Framework
John Kotter’s Model of Change, although not widely utilized in nursing until more recent
years, has provided a model to effectively introduce change into an organizational environment
(Schmidt & Brown, 2015). Kotter proposed an 8-step change model which has been described
as a “top down” transformation process, an effective strategy to implement changes in phases
while encompassing strategies to overcome barriers and challenges (Schmidt & Brown, 2015).
This model was determined to be well suited to this DNP project due to its simplicity and focus
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on changing group behavior. The eight steps include (a) establishing a sense of urgency, (b)
creating a powerful guiding coalition, (c) developing a vision, (d) communicating the vision, (e)
empowering others to act on the vision, (f) planning for and create short-term wins, and (g)
institutionalizing new approaches (Borkowski, 2016).
Application of Theoretical Framework to EBP Project
The first step of Kotter’s 8-step process involves creating a sense of urgency
(Borkowski, 2016). Within this DNP project, a sense of urgency was established as tribal
leaders recognized a growing problem with opioid overdoses. A recent survey among the tribal
members had highlighted that prescription misuse was occurring at much higher rates than
presumed (Great Lakes Inter-Tribal Epidemiology Center, 2016). It became evident that it was
only a matter of time before an unintended overdose occurred within the clinic population. Clinic
X’s health care providers were invited to attend symposiums with local, regional, and national
leaders that addressed the significance of rising rates of overdoses within the community and
further supported the need for an intervention to urgently address the problem. Although a
policy that was developed solely by the clinical manager had been developed, the providers had
voiced concerns that, to prevent unintentional harm and ensure they were incorporating current
safety and risk mitigation strategies, they needed to have access to the most current opioid
prescribing guidelines.
The second step of Kotter’s process involves creating a coalition (Schmidt & Brown,
2015). This task was easily completed as various stakeholders including governmental leaders,
tribal police, health department administration, and prescribing providers all recognized the
significance of the problem. A controlled substance (CS) task force, comprised of the clinical
manager and all five providers, was formed to review, and address any gaps within current
practice standards and policies.
The third step within Kotter’s process involves developing a vision (Schmidt & Brown,
2015). The singular vision of the CS task force was to promote the safe prescribing of high-risk
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substances in order to prevent unintentional consequences. However, it was understood that to
accomplish this greater vision, the task had to be undertaken in a systematic fashion: reviewing
current practices, identifying gaps and variances from recent practice change
recommendations, and implementing practice changes to address identified issues.
These previous steps led to the fourth step, communicating the vision (Schmidt & Brown,
2015). Although key stakeholders all recognized the sense of urgency regarding this matter,
several felt that available information was not only confusing, but was also, at times, conflicting.
The clinical manager and providers were supportive in allowing the DNP student facilitator to
take the lead on this task force, finding relevant information and communicating to appropriate
stakeholders, both within the health department and throughout the tribal government of the
DNP project facility. Regular communication throughout the gap analysis, evidence search, and
policy development was essential to maintaining the vision.
Establishing urgency, creating a coalition, developing a vision, and communicating that
vision, while being the bulk of the process, do not result in practice and organizational changes.
The fifth step in the 8-step process is actually the beginning of intended changes (Schmidt &
Brown, 2015). During the fifth stage, empowering others to act on the vision becomes
imperative for organizational change (Borkowski, 2016). The ability to remove barriers to
proceed with change, as well as use creative thinking and problem solving, becomes imminent
to the success of EBP implementation. Within this DNP project, utilization of the first four steps
provided a foundation which successfully empowered others and ultimately garnered Clinic X’s
administrative support to pursue practice changes. Key stakeholders’ attendance to the
symposiums prompted non-clinical administrative personnel as well as clinical personnel to
recognize the magnitude and urgency of addressing this problem. Perceived barriers
addressed by staff included technical and administrative barriers related to the current EHR,
lack of understanding as to how and when the current policies were developed, fear of creating

NALOXONE CO-PRESCRIBING

13

a sense of mistrust or insulting current patient populations with potential misplaced stigmas, and
a general lack of knowledge regarding current recommended guidelines.
Kotter’s sixth step involves planning for and creating short-term wins (Borkowski, 2016).
This was achieved through regular reporting by the DNP student facilitator of status and
naloxone distribution updates throughout the implementation stage. Providers and the clinical
manager expressed a sense of empowerment and satisfaction towards combating the opioid
epidemic in the project facility. The sense of accomplishment of contributing to the solution
(overdose prevention) rather than contributing to the problem (opioid misuse and overdose) was
crucial in maintaining the enthusiasm that would anchor practice changes.
The seventh step in Kotter’s change model, consolidating improvements and producing
more change (Schmidt & Brown, 2015), is the last step prior to institutionalizing changes. The
seventh step, while sequential in the process, occurred concurrently with step six during this
DNP project. Small wins in the sixth step fueled motivation to continue to examine other
process improvements that could be implemented to support the vision created in step two of
the change process.
The eighth and final step in Kotter’s change model involves institutionalizing new
approaches (Borkowski, 2016). This step is crucial in the process. Without it, practice changes
may not be anchored, providers may become unmotivated or lackadaisical; therefore, practice
improvements have the potential to return to previous status. To mitigate this potential pitfall,
communication and updates were provided at monthly provider meetings and shared
periodically at monthly all-staff meetings. Staff who may not have been directly involved in the
task force, due to lack of prescribing privileges, were also included to lessen stigma surrounding
overdose education and naloxone distribution (OEND) and to provide prescribing providers
support in DNP project interventions. To further anchor change, plans were made for the DNP
student facilitator to continue to act as the clinical champion after the project intervention period
ended. The clinical manager will also remain involved and will be responsible for the
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procurement of additional naloxone stock. Updates and necessary modifications will continue to
be discussed at monthly provider meetings.
Strengths and Limitations of Theoretical Framework for EBP Project
While Kotter’s model has identified creating a sense of urgency as the impetus for
change, individuals have often been motivated by an emotional trigger to act. Although the
Kotter model has been identified as a team-based model, individuals may be at different levels
of priority in terms of urgency, thus creating an imbalance of motivation. However, if individuals
have experienced a situation which created an emotional investment in the necessitated
change, that experience could spur them to action at a faster pace (Schmidt & Brown, 2015).
Within Clinic X, although the DNP student project facilitator was the first to broach the topic of
overdose prevention with the other providers, they quickly became emotionally motivated after
attending the aforementioned symposia and grasping the breadth of the problem at hand.
Also, as Kotter’s model has been identified as a team-based model, it also became
evident that it was initially developed to be delivered from a management position (Schmidt &
Brown, 2015). Yet, having the right mix of team members has been imperative to success, as a
team that is composed of a higher ratio of management staff might foster a sense of
intimidation. It has also been deemed important to maintain a balanced and well-round coalition
of stakeholders, since a variety of experiences and opinions can provide an environment to
create and sustain practice changes (Schmidt & Brown, 2015).
A significant limitation of applying Kotter’s change model to this DNP project was the
time constraints in which to fully deploy and anchor change within the organization. Since the
DNP project was conducted in a relatively brief window of time, it was difficult to spend an
ample amount of time on each sequential step. The limited time for implementation had the
potential, for those who may have been faced with a heavier workload than usual to implement
project driven practice changes, to develop a sense of burden, rather than empowerment.
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Therefore, it became essential to pay close attention to step six, creating short term wins (to
acknowledge their successes) to continue to propel change.
Evidence-based Practice Model
Melnyk and Fineout-Overholt (2015) stated that “It is not enough to have knowledge of
the best evidence to guide clinical practice; that knowledge must be translated into clinical
practice to improve patient care and outcomes.” (p. 202). While many health care providers
have been highly motivated to integrate EBP into their clinical routines, the processes may be
fraught with organizational obstacles. Incorporating a systematic process model to guide the
implementation of EBP can be beneficial to anticipate and overcome these barriers.
Overview of EBP Model
The Iowa Model of Evidence-Based Practice to Promote Quality Care has been used
successfully within hospitals and other organizations to guide implementation of EBP (Melnyk &
Fineout-Overholt, 2015). This process model was originally developed in 1994 by M. Titler and
was based on her experiences (Melnyk & Fineout-Overholt, 2015). Based on feedback from its
users, the model has undergone revisions, indicating that as our knowledge fund of
implementing EBP has expanded, thus too must the model change to incorporate our improved
utilization (Titler et al., 2001). The revised model included new terminology and feedback loops,
addressed changes in the health care market, and supported the use of other types of evidence
when research findings were unavailable to guide practice (Titler et al., 2001).
The first step of the Iowa Model is to identify a problem focus or knowledge focus
trigger where an EBP change may be warranted (Melnyk & Fineout-Overholt, 2015). The next
step in the process is to determine if the problem is identified as a priority for the organization.
This an important step in the process because identifying a problem as a priority to the
organization will help garner support to complete the EBP project (Melnyk & Fineout-Overholt,
2015). The following step includes assembling a team of stakeholders which will help to
develop, implement, and evaluate practice change (Melnyk & Fineout-Overholt, 2015). Once
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the team is assembled, they will need to evaluate and synthesize available literature. At this
junction, a decision point is encountered. If it is determined that there is not enough literature
available, the team may decide to conduct the needed research themselves or base practice on
other types of research such as case reports, expert opinions, scientific principles, or theories.
Otherwise, if it is determined that there is enough available literature to proceed, the team will
conduct a pilot change within the practice setting. At the conclusion of the pilot, the team will
evaluate if the change was appropriate to be adopted into practice or if additional changes need
to be made. If it is appropriate, the practice change will be implemented, and the results
disseminated (Melnyk & Fineout-Overholt, 2015).
Application of EBP Model to EBP Project
The Iowa Model was chosen for this project because it provided an organized teambased approach to implementing evidence-based practice changes. Initially, a problem-focused
trigger was identified: co-prescribing of naloxone was identified as a risk mitigation strategy in
recent guideline updates but was not actively being done by prescribing providers within the
DNP project facility (CDC, 2016a). It was determined that, due to recent heightened awareness
of potential overdose risks within the community, this problem was indeed a priority. As
indicated by the step-wise approach of the Iowa Model, a team was assembled to develop,
implement, and evaluate an EBP change. The team was comprised of several multi-disciplinary
members, including the clinical manager, the DNP student facilitator, and the prescribing
providers (two PAs and two physicians). The PICOT question was formed, and a thorough
literature search was conducted.
After the literature search was conducted, relevant findings were appraised and
synthesized to identify the current best practice to improve provider co-prescriptions rates of
naloxone. The pilot intervention change in practice was identified and a detailed plan of the
intervention and evaluation strategies was submitted to Valparaiso University’s institutional
review board (IRB) for approval. As the project facility did not have a formal IRB, team
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members reviewed the proposed intervention for any concerns during a regularly scheduled
meeting. After all approvals were obtained, the project intervention was implemented into a pilot
practice change. Finally, the project intervention was reviewed at the completion of the pilot
period and results were analyzed, reviewed, discussed, and anchored into a practice change.
Ongoing monitoring and analysis of the current EBP literature and intervention continue to
ensure the intervention remains relevant and appropriate.
Strengths and Limitations of EBP Model for EBP Project
The Iowa Model possessed several strengths to guide this project. First, although
developed by members of the nursing profession, it provided a simplified approach that has
been easily understood by a variety of members within a multi-disciplinary team (Melnyk &
Fineout-Overholt, 2015). Second, the Iowa Model provided a systematic, step-wise approach
with key decision points on whether to proceed or return to previous steps, thus ensuring best
methods were utilized throughout the process. Finally, although this EBP project was led by the
DNP student facilitator, the Iowa Model supported a process which incorporated team members
to be actively involved, which improved stakeholders’ investment within the intervention.
A limitation of utilizing the Iowa Model to guide this EBP project would be the time
constraints of the continued process for ongoing analysis and implementation. As this project
intervention was conducted on a timeline directed by the educational partnership, there was no
opportunity to continue with appropriate revisions to the intervention or further analysis of those
revisions. Furthermore, the model did not provide guidance to the team through the data
collection and analysis component, which limits its applicability for disseminating project findings
to other practitioners who may want to replicate the project themselves. Specific input regarding
analysis and data collection could be beneficial for future revisions of the model and applicability
to EBP projects.
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Literature Search

Sources Examined for Relevant Evidence
An extensive literature search was conducted using multiple database sources including
CINAHL, PsychINFO, Joanna Briggs Institute, Cochrane Library, MEDLINE (via EBSCO),
ProQuest, and PsychArticles. Due to the rapidly changing literature available regarding this
topic, an extensive hand search was also completed in an effort to obtain all current relevant
research available. A variety of keywords and medical subject headings (MeSH) were trialed
during this search. The final set of terms utilized during the literature search included “naloxone
AND prescri* AND opioid* OR opiate* AND primary OR pharm*.” A complete list of the search
terms and number results found in each database can be found in Table 2.1.
Inclusion criteria for the literature search encompassed a publication date between 2015
and 2017, English language, scholarly or academic journals, and peer-reviewed journals. The
narrow, recent publication window was selected since the CDC opioid prescribing guideline
(CDC, 2016a), which had been adopted by most, if not all major organizations was introduced in
March 2016, thus making many previous studies obsolete or clinically irrelevant. Since the
CDC’s guideline was particularly relevant to this project, the literature search focused on
evidence that was published near or after the time of guideline release.
The literature search yielded 259 articles, of which 65 were duplicates. A review of titles
and abstracts resulted in 36 articles being deemed worthy of further review based on inclusion
criteria. After reviewing the 36 articles, the DNP student facilitator selected a total of eight
articles based on level of evidence and quality of evidence. Additional hand searching resulted
in two other articles being included within the final evidence table (Table 2.2).
Articles were included if they pertained to prescribing providers, were in primary care or
outpatient clinic settings and had interventions related to naloxone co-prescribing rates.
Exclusion criteria included evidence that specifically pertained to (a) hospital settings, (b)
community-based distribution programs, (c) emergency medical services naloxone
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administration, (d) police naloxone administration, and (e) oncology diagnoses. Evidence was
also excluded if the intervention focused only on patient populations, rather than health care
providers, or if pregnancy was involved. Articles that included use of pharmacists or pharmacybased distribution were evaluated individually for relevance and considered for inclusion if they
utilized interventions that could either be incorporated into a primary care setting or if they
utilized interventions to improve naloxone co-prescribing rates.
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Table 2.1
LITERATURE SEARCH RESULTS
DATABASE

SEARCH TERMS

LIMITERS

CINAHL

naloxone AND prescri* AND
opioid* OR opiate* AND
primary OR pharm*
naloxone AND prescri* AND
opioid* OR opiate* AND
primary OR pharm*
naloxone

2015-2017,
English, PeerReviewed
2015-2017,
English, PeerReviewed
2015-2017
2015-2017,
Cochrane
Reviews
2015-2017,
English, PeerReviewed
2015-2017,
English, PeerReviewed

Handsearching

naloxone AND prescri* AND
opioid* OR opiate* AND
primary OR pharm*
naloxone AND prescri* AND
opioid* OR opiate* AND
primary OR pharm*
naloxone AND prescri* AND
opioid* OR opiate* AND
primary OR pharm*
“naloxone” in abstract
naloxone AND prescri* AND
opioid* OR opiate* AND
primary OR pharm*
naloxone

TOTAL

N/A

PsychINFO

Joanna Briggs
Institute
Cochrane

MEDLINE (via
EBSCO)
ProQuest

PsychArticles

2015-2017,
English, PeerReviewed
2015-2017,
English
N/A

ARTICLES
YIELDED
30

DUPLICATES
0

ABSTRACTS
RIVEWED
11

ARTICLES
USED
2

43

9

11

0

4

0

0

0

5

0

0

0

102

47

12

6

39

9

2

0

0

0

0

0

0

0

0

2

259

65

36

10
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Levels of Evidence
A total of 10 sources of evidence were deemed worthy for inclusion into the supportive
literature for this EBP: one randomized controlled trial (RCT), two quasi-experimental, two
descriptive studies, three program evaluations, one quality improvement project, and one
consensus statement. The ten sources were evaluated using the Johns Hopkins Research
Evidence Based Practice Research Appraisal Tool, and an evidence level was assigned,
ranging from level I to level V, with level I being the highest level of evidence and level V, being
the lowest level respectively (Dearholt & Dang, 2014). The sources in the literature review were
further appraised for quality utilizing the Johns Hopkins Nursing Evidence-Based Practice
Research Evidence Appraisal Tool or the Non-Research Evidence Appraisal Tool (Dearholt &
Dang, 2014).
Using the Johns Hopkins Research Evidence Based Practice Appraisal Tool, research
studies receive a level of I, II or III, depending on their design. RCTs or experimental studies
receive the highest level of I, while quasi-experimental studies are considered a level II, and
non-experimental or qualitative studies are considered a level III (Dearholt & Dang, 2014).
Likewise, summaries of multiple research studies are stratified in a similar manner. Systematic
reviews, meta-analysis and meta-synthesis studies are appraised with consideration of the
studies included within the reviews. For example, if all the studies contained within the review
are RCTs, a level I would be given. If studies are a combination of RCTs and quasiexperimental or quasi-experimental only, a level II would be appropriate. A level III rating is
given if the studies included with the review are a combination of RCTs, quasi-experimental and
non-experimental studies, or non-experimental studies only. If any of the studies contained
within the systematic review are qualitative, then a level III is required (Dearholt & Dang, 2014).
The Johns Hopkins Non-Research Evidence Appraisal Tool rates other evidence in
much the same fashion. Clinical practice guidelines, consensus or position statements are a
level IV, while literature reviews and expert opinions are given a level V ranking. Additionally,
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organizational experiences are appraised as a level V if they are quality improvement initiatives,
financial evaluations, or program evaluations. Case reports, community standards, clinician
experience and consumer preference are also considered a level V (Dearholt & Dang, 2014).
The DNP student facilitator ranked the literature that was included for relevant evidence
by the standards explained above. The one RCT (Behar, Rowe, Santos, & Coffin, 2017) was
ranked as level I evidence. Two pieces of evidence were considered level II: a retrospective,
repeated measures cohort study (Bounthavong et al., 2017) and a quasi-experimental study
(Coffin et al., 2016). Two pieces of evidence, both descriptive studies were considered a level
III (Behar et al., 2016; Winograd, Davis, Niculete, Oliva, & Martielli, 2017). The bulk of the
evidence collected was considered non-research and was leveled as such. One consensus
statement was rated as a level IV (Alexander, Frattaroli, & Gielen, 2015), while the remainder of
the evidence pieces were ranked as level V: three program evaluations (Devries, Rafie, &
Polston, 2017; Oliva et al., 2017; Wilson et al., 2017), and one exploratory pilot project
(Delaney, Huff, Mini, Thomas, & Tremaglio, 2016),.
Appraisal of Relevant Evidence
The ten pieces of evidence in the literature reviewed were also appraised for quality,
using the Johns Hopkins Research and Non-Research Evidence Appraisal Tools. These tools
incorporate the use of quality ratings based on quality appraisal; there are three different quality
levels: (A) high quality, (B) good quality, and (C) low quality or major flaws (Dearholt & Dang,
2014).
In relation to pieces of evidence that are appraised with the Johns Hopkins Research
Evidence Appraisal Tool, a grade A, high quality, rating is reached if the study is consistent, with
generalizable results, sufficient sample size for the study design, adequate control, definitive
conclusions, and if there are consistent recommendations based on comprehensive literature
review that includes thorough reference to scientific evidence (Dearholt & Dang, 2014). A grade
B, good quality, rating is achieved if there are reasonably consistent results, sufficient sample
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size for the study design, some control and fairly definitive conclusions, and reasonably
consistent recommendations based on fairly comprehensive literature review that includes some
reference to scientific evidence (Dearholt & Dang, 2014). A low quality, grade C, is given if
there is little evidence with inconsistent results, insufficient sample size for the study design, or if
conclusions cannot be drawn (Dearholt & Dang, 2014).
The Johns Hopkins Non-Research Evidence Appraisal Tools are evaluated more
specifically to the type of evidence being evaluated but are still given the same quality levels:
(A) high quality (B) good quality and (C) low quality or major flaws (Dearholt & Dang, 2014).
Level IV evidence (i.e., clinical practice guidelines, consensus, or position statements) are
evaluated in regards to (a) material officially sponsored by a professional, public, or private
organization or government agency; (b) documentation of a systematic literature search
strategy, (c) consistent results with sufficient numbers of well-designed studies, (d) criteriabased evaluation of overall scientific strength and quality of included studies and definitive
conclusions, and (e) national expertise that is clearly evident and has been developed or
revised within the past five years. If the previous criteria are met, a high quality (A) rating would
be given (Dearholt & Dang, 2014). A good quality (B) rating would be considered if the material
meets the criteria above, but only indicates a reasonably thorough and appropriate systematic
literature search strategy, reasonably consistent results, and there is evaluation of strengths and
imitations of included studies with fairly definitive results (Dearholt & Dang, 2014). A low quality
or major flaws rating (C) would be given if the literature (a) was not sponsored by an official
organization or agency, (b) included an undefined, poorly defined or limited literature search
strategy, (c) had no evaluation of strengths and limitations of included studies, (d) presented
insufficient evidence with inconsistent results, (e) lacked the ability to derive conclusions, or (f)
had not been revised within the last five years (Dearholt & Dang, 2014).
Level V evidence for organization experience is awarded a high quality (A) rating if there
are clear aims and objectives, consistent results across multiple settings, formal quality
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improvement or financial evaluation methods used, definitive conclusions, and consistent
recommendations with a thorough reference to scientific evidence (Dearholt & Dang, 2014). A
good quality (B) rating meets the majority of the high quality (A) criteria but has consistent
results in only a single setting and/or reasonably consistent recommendations with some
reference to scientific evidence (Dearholt & Dang, 2014). A low quality of major flaw (C) rating
is appropriate when there is unclear of missing aims or objectives, inconsistent results, or poorly
defined quality improvement/financial analysis method, or when recommendations cannot be
made (Dearholt & Dang, 2014).
When Level V evidence (i.e., literature reviews, expert opinions, community standards,
clinician experience, and consumer preference) is evaluated, a high quality (A) rating is
appropriate if the expert provides clearly evident expertise, draws definitive conclusions,
provides scientific rationale, and is recognized as a thought leader in the field. A good quality
(B) rating is given if the author’s expertise appears to be credible and he or she draws fairly
definitive conclusions and provides logical argument for opinions. Finally, a low-quality, major
flaws (C) rating is indicated if the author’s expertise is not discernable or is dubious or if
conclusions cannot be drawn (Dearholt & Dang, 2014).
Level I Evidence
Behar et al. (2017) conducted a good quality (B rating) study that included an academic
detailing (AD) intervention to 40 randomly selected opioid prescribing primary care providers (n
= 40, N = 143) in the San Francisco area over a 3-month time frame in 2015. Written materials,
including a patient brochure and a provider educational booklet, were developed under the
guidance of appropriate experts within the field. The provider educational booklet included
information on state and national opioid overdose statistics, patient-level overdose risk facts,
rationale for furnishing a naloxone co-prescription to patients receiving long term opioids,
naloxone pharmacology, effectiveness and cost effectiveness of naloxone, and indicators for
prescribing, as well as guidance on how to educate patients on naloxone and opioid overdoses.
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Information regarding state laws and examples of how to prescribe depending on formulation
type were also included. A detailing visit reviewed the developed materials and a 1-page
instruction sheet for registering for the prescription drug monitoring program, a 1-page opioid
morphine milli-equivalent (MME) calculator, and two articles addressing the effectiveness and
cost effectiveness of naloxone. The academic detail included a 5- to 60-minute (m = 28
minutes) discussion regarding the elements of the handouts. Discussions were not fixed, but
instead were tailored to meet the needs and interests of the individual providers. Providers
were contacted two to three months after the detailing and again at six to nine months after the
intervention to establish if they had, indeed, prescribed naloxone.
Medi-Cal data for each provider was obtained, including the number of naloxone
prescriptions that had been filled in the four months before and after the intervention. Among
the detailed providers, the number of providers that issued naloxone prescriptions increased
from 0 to 3 providers, while the number of naloxone prescriptions filled increased from 0 to 10
prescriptions filled. Behar et al. (2017) reported a statistically significant increase in naloxone
prescriptions (p = 0.10) compared to those who did not receive the intervention, IRR 11.0, 95%
CI [1.8, 67.8].
Behar et. al (2017) concluded that academic detailing addressing opioid safety and
naloxone prescribing, was not only well-received by primary care providers who received it, but
also significantly increased the naloxone co-prescription rates compared to those who did not.
The findings supported that naloxone academic detailing can be an effective method to improve
naloxone co-prescribing rates among primary care providers. Thus, this study provided
evidence to support this DNP project.
Level II Evidence
Bounthavong et al. (2017) conducted a good quality (B rating) study to evaluate the
effects of an academic detailing service given to prescribing providers on naloxone coprescription rates between October 2014 to September 2016 in the Veterans’ Affairs. Their
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retrospective, repeated measures cohort study evaluated 750 primary care providers who had
received at least one academic detailing (AD) service during the study period. Academic
Detailers were trained clinical pharmacists who provided individualized, face-to-face interactions
to deliver evidenced-based-research, data tools and educational materials in an effort to change
prescribing behaviors and promote guideline adherence. Providers may have been aware of
OEND programming but were categorized as unexposed until an AD training occurred.
Of the 3313 providers, 22.6% received at least one OEND specific AD visit. While the
authors did not include raw data reporting, they did conclude that after one year, the average
number of naloxone prescriptions showed a statistically significant increase (p < .001) in the
exposed group than the unexposed providers with IRR 3.2, 95% CI [2.0, 5.3]. At two years, the
average number of naloxone prescriptions continued to demonstrate a statistically significant
increase (p < .001), again with a IRR 7.4, 95% CI [3.0, 17.9]. Although the authors pointed out
that it was likely that an increased awareness of OEND programs grew during this period,
naloxone prescribing from baseline to two years in the AD exposed providers still exhibited a
7.1% higher average compared with AD-unexposed providers (95% CI [2.0%, 12.5%]).
Bounthavong et al. (2017) concluded that although AD interventions have been
successful in other attempts to align provider compliance to guidelines (e.g., hypertension or
judicious use of antibiotics), this was the first study that supported AD for OEND in primary care
settings. The findings supported that naloxone academic detailing can be an effective method
to improve naloxone co-prescribing rates among primary care providers. Thus, this study
provided evidence to support the intervention used within this DNP project.
Coffin et al. (2016) conducted a high quality (A rating) study evaluating the effects of a
non-randomized intervention on naloxone co-prescription for primary care patients receiving
long-term opioid therapy for pain. This study took place between February 2013 to April 2014 in
the San Francisco area, among six safety net clinics which had reported deaths from opioid
related overdose between 2010 to 2012.
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At each of the sites, an “onsite leader” or champion was selected to deliver a consistent
protocol which began with academic detailing for providers. This detailing included rationale
and indications for prescribing naloxone, appropriate language to approach patients to reduce
stigma, naloxone formulations and pharmacy/payor coverage. Providers and staff were also
educated on how to train patients and family members on naloxone use and how to recognize
an opioid overdose. Training was provided approximately 30 days prior to the initiation of
naloxone co-prescribing. After the initiation of the naloxone co-prescribing program, additional
training and at least one follow-up email were also completed.
Of the 1985 patients receiving long term opioids, 38.2% (n = 759) were given a naloxone
co-prescription during the 2-year study. Naloxone co-prescribing was not implemented at the
clinics until the start of the study; therefore, none of the patients had previously received a
naloxone prescription. Although more extensive statistical review of data was completed
regarding decreases in emergency department visits and daily MME changes, the authors did
conclude that naloxone could successfully be prescribed in a primary care setting. Providers
who were given an AD session were advised to offer naloxone to all patients receiving opioids;
however, many providers still prioritized naloxone co-prescribing to patients with higher
established risk factors. Despite this finding, the authors also concluded that providing
naloxone through a primary care setting may have ancillary benefits, such as reducing opioid
related deaths.
Coffin et al. (2016) concluded that the use of a clinical champion who conducted
naloxone academic detailing sessions in the primary care setting could be an effective method
to increase naloxone co-prescribing. Thus, this study provided additional evidence to support
the intervention and targeted outcomes for this DNP project.
Level III Evidence
Behar et al. (2016) explored the acceptability of naloxone co-prescriptions among
primary care providers who were treating patients on long-term opioid therapy for pain. Behar
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et al., in collaboration with Coffin et al. (2016), administered surveys electronically four to eleven
months after Coffin et al.’s naloxone co-prescribing initiative began. These surveys were
distributed to providers in six San Francisco safety net clinics, which via Coffin’s et al. (2016)
intervention, received at least one AD session prior to the initiation of naloxone co-prescribing
practices within those clinics. Nearly 70% of all providers receiving training in the Coffin et al.
study (111 of 176) completed the survey. Results indicated that the majority of responding
providers (79.3%) had prescribed naloxone since the initiative began, and almost all (99.1%)
indicated that they would be “somewhat to very likely” to prescribe naloxone in the future.
Providers reported a willingness to prescribe to an expanded number of subgroups, including
those on either high dose (>20 MME) or low dose (<20 MME) opioids (97.7% and 59.8%,
respectively), the elderly, and those without a history of previous overdose.
This good quality (level A rating) study supported the premise that providers are willing
to prescribe naloxone after they receive the AD (the intervention used within Coffin et al., 2016),
and the researchers identified areas which need to be further addressed, through additional AD
or via other means. Behar et al. (2016) noted that the Coffin et al. intervention was completed
before the release of newer CDC guidelines for safe opioid prescribing (CDC, 2016a) and
therefore, the Behar et al. (2016) responses were truly reflective of the AD Coffin et al. (2016)
provided.
The study findings supported evidence that providers in a primary care setting could
increase their willingness to prescribe naloxone after receiving an academic detailing session
and, thus, AD could be an effective method to improve naloxone co-prescribing rates among
primary care providers. Therefore, this high quality (grade A) study provided additional evidence
supporting the creation of a coalition within the team-based approach of the Kotter model used
within this DNP project.
Winograd et al. (2017) published a good quality (B rating) study conducted within the
Veteran’s Health Administration (VHA) that aimed to answer three questions: (a) How
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knowledgeable and comfortable are providers regarding the clinical incorporation of OEND? (b)
If providers have concerns, what is their nature and magnitude? and (c) Does knowledge or
concern vary by practice setting and profession? Surveys were administered to prescribing
providers within the VHA system prior to an AD session regarding OEND. Each of these
sessions, lasting 25 to 40 minutes, included a brief review of current overdose death rates and
trends, overdose risk factors, and preventions methods, naloxone rescue devices, guidance on
OEND patient trainings, theoretical and practical barriers as well as strategies for successful
implementation.
Forty-five participants including physicians, psychiatrists, residents, and “non-physicians”
(nurse practitioners, physician assistants and clinical pharmacists), completed the survey. Prior
to the AD session, results indicated that providers were more concerned with potential negative
consequences of OEND implementation, and they were less concerned about unsafe opioid
prescribing practices.
Winograd et al. (2017) noted that after the OEND training was presented, prescriptions
rates rose 331%, while the total prescribers of naloxone increased 323% compared to the 10month period prior to the OEND training. The researchers stated, “although any relationship
between training and increased prescription rates should of course be interpreted with extreme
caution in the absence of data linking training attendees to their prescribing patterns, these
changes may at least partially reflect the impact of the in-services” (p. 138.).
Winograd et al. (2017) concluded that OEND training appeared to be associated with
increasing rates of naloxone prescribing as well as increasing the number of actual prescribers.
They further noted that the findings provided evidence for the need of increased OEND
implementation efforts among settings where opioids are prescribed, particularly primary care
settings. The findings, within this good quality (B rating) study, supported that naloxone
academic detailing can be an effective method to improve naloxone co-prescribing rates among
primary care providers.
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Level IV Evidence
Alexander et al. (2015) provided high quality (grade A) recommendations for an
evidence-based approach to combat the prescription opioid epidemic. The authors of this
consensus, from the well-known leader in research and evidence-based practice Johns
Hopkins, met with experts from a multitude of disciplines for a town-hall style meeting where
they reviewed available evidence and developed three guiding principles for actionable
recommendations. Applicable to this DNP project, the clinical experts discussed the role of
OEND programs in promoting appropriate and safe use of prescription opioids.
Consistent with the strategy developed for this DNP project, the experts recognized that
the actionable strategy was to engage health care providers to advance the co-prescription of
naloxone. Their recommendations supported the role of a clinical champion for naloxone as an
effective method to improve naloxone co-prescribing rates among primary care providers.
Level V Evidence
A good quality (B rating) pilot project, led by Delaney et al. (2016) sought to increase
naloxone co-prescription rates among four primary care offices in western Connecticut. This
quality improvement (QI) project had two primary objectives: (a) to increase the number of
naloxone co-prescriptions written and (b) to explore best practices in developing a coprescription program in a primary care setting.
The authors first examined baseline rates of naloxone prescriptions by reviewing EHR
records. A clinical champion, either a third-year resident or a clinician educator, created a log of
all patients that would be eligible for naloxone co-prescriptions. When patients presented to the
clinic for scheduled refills from February to April 2015, the eligible patient was approached by
the person who maintained the log and offered a pre-determined naloxone co-prescription. If the
patient stated he or she was interested, an additional appointment was scheduled for a patient
teaching session prior to the prescription being provided.
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Baseline data revealed that zero naloxone prescriptions had been written prior to the
beginning of the QI project. Following the intervention, among the four clinics, approximately
26% of identified individuals were given a naloxone co-prescription. While the QI project did
produce positive outcomes, the authors noted that they encountered several barriers, and as a
result, they provided several recommendations for other practices wishing to implement
naloxone co-prescribing. Notably, the relevant recommendation to this DNP project included
establishing a provider champion at each site (Delaney et al., 2016).
Delaney et al. (2016) concluded that the use of a clinical champion in a primary care
setting was an effective way to increase naloxone co-prescriptions. Thus, this study provided
evidence to support the intervention for this DNP project, but also provided additional
information regarding targeted outcomes and anticipated barriers to implementation.
Consistent with more recent quality improvement initiatives to address the opioid crisis,
Devries et al. (2017) (high quality, level A rating) implemented a program to increase OEND
within the University of California San Diego Health System.

This health system serves as the

San Diego County safety net hospital and includes 563 hospital beds and 6 pharmacies, with a
total of 636,118 outpatient visits in 2015. Their goal, to increase take-home naloxone with the
ultimate goal of preventing fatalities, focused on AD for providers, dissemination of patient
education materials, EHR changes to promote naloxone prescriptions, and availability of
naloxone in pharmacies. AD was provided via departmental trainings lasting 15 to 60 minutes,
posting of bulletins, and email notifications. Training included criteria for prescribing,
epidemiology of opioid overdose and health disparities, evidence for naloxone distribution,
methods of naloxone administration, EHR steps for prescribing, and related prescribing and
liability laws. The training was provided to 252 of 905 eligible physicians, pharmacists, nurses
and pharmacy technicians, including 184 of 533 eligible providers with prescriptive authority.
These combined efforts resulted in 245 doses of naloxone being co-prescribed between
January and October 2016. This intervention increased the baseline rate of naloxone co-

NALOXONE CO-PRESCRIBING

32

prescriptions ten-fold from 4.5 per month to an average of 46 per month in the three months
following full implementation.
Devries et. al (2017) concluded that academic detailing addressing opioid safety and
naloxone prescribing, in conjunction with patient education materials and EHR changes
significantly increased the naloxone co-prescription rates. Devries et al. (2017) recommended
continued training for providers and the development of a script to assist with difficult patient
conversations regarding naloxone use. The findings supported that naloxone academic
detailing (which included provider training and reminders) can be an effective method to
improve naloxone co-prescribing rates among primary care providers. Thus, this study provided
additional evidence regarding length of time for the AD and EHR reminders to support the
intervention in this DNP project.
As the first major health system to translate a public health community based OEND
approach to a health care system approach, Oliva et al. (2017) (high quality, A rating) examined
the effects of a system-wide quality improvement program to launch the development of a
national opioid OEND program within all 142 VHA facilities. Their concentration was on
developing clinical guidance for issuing naloxone kits as well as developing focal campaign of
AD. Their program processes included seven steps, the first being to establish at least one
clinical champion at each facility to speed OEND implementation. This clinical champion then
worked with leadership to develop an overall OEND roll-out implementation plan. VHA
leadership also recommended that the clinical champion determine what material, resources,
and protocols were necessary. By doing this, the clinical champions would garner support for
overall project success.
As the processes continued, Oliva et al. (2017) reported that VHA efforts varied in the
AD of their providers, from individual training of staff by the clinical champion to community
partners and train-the-trainer models. It was also deemed important to leverage existing staff

NALOXONE CO-PRESCRIBING

33

and resources to implement OEND to patient populations by using brochures, mailing flyers,
and displaying posters to increase overall awareness of programming.
Between October 2015 to September 2016, VHA AD services completed more than
3900 individualized evidence-based OEND education outreach visits and has had consultation
with more than 7000 VHA providers. Although no written baseline data was provided, a graph
depiction embedded in the article indicated a sharp quarterly rise in naloxone prescriptions
dispensed beginning in the first quarter of 2015, the time indicated as the first documented
national AD session. By the end of fiscal year 2016, 5693 VHA providers had written a total of
45,178 naloxone prescriptions for 39,328 patients.
Although much of the original program continues as was originally designed, Oliva et al.
(2017) noted that naloxone co-prescribing practices have been amended to include one refill, so
patients always have access to naloxone in case of an emergency. Further, they opined that
AD can play a critical role in facilitation of OEND implementation. “Medical facilities should
consider developing academic detailing programs to maximize the benefits in achieving optimal
OEND implementation and sustainability.” (Oliva et al., 2017, p. S176).
Additional lessons learned from this system-wide program address the importance of
engaging patients, leaders, and staff across the clinical setting. Oliva et al. (2017) also noted
that having a champion with dedicated time to support and facilitate OEND implementation is
ideal. This study supported the use of a clinical champion with time to develop and administer
patient education materials in addition to the delivery of AD sessions to clinical staff as an
effective way to increase naloxone co-prescriptions.
Similar to the work in the VHA system, Wilson et al. (2017) drew upon the best available
evidence to design and implement a targeted naloxone co-prescribing program within a large
academic family medicine practice in western North Carolina. Their project used a pharmacist,
who manually reviewed the EHR and identified those meeting criteria for naloxone coprescriptions, as the clinical champion. The clinical champion then provided an AD session to
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providers which covered four main topics. First, opioid epidemic awareness focused on national
and local statistics of the opioid epidemic, a harm reduction approach, the role of naloxone as
an opioid overdose reversal agent, and previous successes with community-level distribution of
naloxone. The second topic addressed emergency management, including overdose
recognition and what to do when an overdose is witnessed. The third focus (naloxone
administration) discussed formulations of naloxone, directions for use, onset of action, and
when to re-dose. Finally, financial considerations (e.g., insurance coverage of naloxone
formulations and billing for clinical encounters when prescribing naloxone) were covered.
Wilson et al.’s (2017) baseline data indicated that 709 of the audited 1297 patients were
identified as chronic opioid users; 350 of the chronic users (49.4%) met criteria for naloxone coprescriptions, but only 3.4% had naloxone on their medication list. The program took four
months to develop and implement, achieving full implementation in September of 2016. It is
notable that this project evaluation planned assessments at 3-, 6-, 12- and 18-months postimplementation. Thus, although this project was fully implemented on September 2016, Wilson
et al. (2017) noted that the manuscript was submitted for publication in August 2016, making it
impossible to discuss the impact of these interventions (Wilson et al., 2017).
Although this piece of evidence did not yet have results available thus earning a low
quality (C rating), the authors did outline a systematic evidence-based approach for increasing
naloxone co-prescriptions within a family practice. Wilson et al. (2017) determined that the use
of a clinical champion within the clinical setting, who developed and delivered an AD session,
was the most likely to have the desired outcomes. Thus, this piece of evidence provided
additional support for the use of a clinical champion and AD sessions as a best practice for
increasing naloxone co-prescribing.
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Construction of Evidence-based Practice
Synthesis of Critically Appraised Literature
A major focus identified throughout the reviewed literature was that current available
research on naloxone co-prescribing and effective interventions to promote co-prescribing is
rapidly changing (Alexander et al., 2015; Behar et al., 2016; Behar et al., 2017; Bounthavong et
al., 2017; Coffin et al., 2016; Delaney et al., 2016; Devries et al., 2017; Oliva et al., 2017; Wilson
et al., 2017; Winograd et al., 2017). Within both the health care and private sectors, an
increased awareness of the purpose and availability of naloxone has become apparent. As a
result, many health care facilities are facing the issue while operating in crisis mode as they
attempt to implement EBP strategies to increase access to naloxone. Thus, there is a need for
the dissemination of additional evidence from EBP projects to reinforce best practice.
Although the systematic literature review highlighted the effects of multi-faceted
strategies to improve naloxone co-prescribing, the most commonly incorporated elements were
the use of AD and clinical champions (Alexander et al., 2015; Coffin et al., 2016; Winograd et
al., 2017; Wilson et al., 2017). Not surprisingly, the literature review indicated that providers
were more likely to co-prescribe naloxone if their level of knowledge about doing so was
increased, and AD sessions were well-documented as an effective means of enhancing practice
change (Behar et al., 2016; Behar et al., 2017; Bounthavong et al., 2017; Coffin et al., 2016;
Delaney et al., 2016; Devries et al., 2017; Oliva et al., 2017; Wilson et al., 2017; Winograd et al.,
2017).
AD sessions carried common themes of rationale and indications for prescribing
naloxone, available naloxone formulations, acquisition and payment information as well as
strategies to initiate and carry out education to patients (Alexander et al., 2015; Coffin et al.,
2016; Winograd et al., 2017; Wilson et al., 2017). Early reviews of several pilot programs using
a multi-faceted approach included the use of AD intervention (Behar et al., 2016; Delaney et al.,
2016; Devries et al., 2017; Oliva et al., 2017; Wilson et al., 2017). While the facilitators of these
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programs acknowledged that many of their results were preliminary, reports of early findings
included positive outcomes.
The use of a clinical champion within the practice setting was another commonly
included intervention within multifaceted interventions (Alexander et al., 2015; Coffin et al.,
2016; Winograd et al., 2017; Wilson et al., 2017). Clinical champions were able to increase the
pace at which OEND programs could be successfully implemented into a practice change; the
use of a clinical champion was also instrumental for determining or developing an appropriate
protocol, identifying or developing training and materials for distribution, and working with
leadership to facilitate a smoother roll-out process. Although not all evidence was specific on the
clinical educational background of the champion, some supported the use of a pharmacist or
another prescribing provider (Wilson et al., 2017).
Additional components of the multifaceted interventions included the use of provider
reminders (e.g., alerts within EHR) (Devries et al., 2017; Oliva et al., 2017; Wilson et al., 2017).
While other researchers addressed enhancing the accessibility of the physical naloxone
prescription (Alexander et al., 2015; Behar et al., 2016; Coffin et al., 2016; Delaney et al., 2016;
Devries et al., 2017; Oliva et al., 2017; Wilson et al., 2017).
All the pieces of evidence reviewed acknowledged that the issue at hand, naloxone coprescriptions, could not be successful with the utilization of a solitary intervention (Alexander et
al., 2015; Behar et al., 2016; Behar et al., 2017; Bounthavong et al., 2017; Coffin et al., 2016;
Delaney et al., 2016; Devries et al., 2017; Oliva et al., 2017; Wilson et al., 2017; Winograd et al.,
2017). Thus, a multifaceted approach was deemed appropriate.
Best Practice Model Recommendation
Utilizing appraised literature was the foundation for this EBP project. The DNP student
facilitator presented the evidence synthesis to the CS task force and conferred with the team to
determine the best practice recommendations that were applicable to the project facility. The
review and synthesis of the best available evidence provided the solid foundation that was
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needed to answer the clinical question and develop a PICOT question when using the Iowa
model for EBP: Among primary care providers in a tribal health clinic, does the introduction of
an multi-faceted intervention, which includes the use of academic detailing and a clinical
champion, versus the current practice of no intervention, improve the co-prescription rates of
naloxone to chronic opioid patients in a twelve week period?
How the Best Practice Model Will Answer the Clinical Question
Results and evidence for the literature synthesis provided the structure for the
development of a multi-faceted OEND intervention. An AD session, which gave step by step
instructions for the logistics of dispensing naloxone within the primary care clinic was
developed. Clarity regarding who would order and maintain available naloxone stock was
attained. A clinical champion was selected (DNP student facilitator) and OEND educational
materials were procured for provider AD sessions; patient education brochures for distribution
during clinic visits and posters for waiting and exam rooms were made available to spark
conversation. AD sessions were held in a group format and additional group follow up and oneon-one sessions were completed when appropriate.
Utilization of the Iowa model incorporates teamwork and collaboration, which was felt to
be a fundamental property to the implementation of this EBP project. The Iowa model was
especially useful in identifying systems problems and investigating potential interventions which
complemented the first three steps of Kotter’s change model and mandated input from the task
force. The team-based dialogue allowed for open communication to voice concerns and
address potential unforeseen barriers to naloxone co-prescribing. The team then determined
that the multifaceted approach was warranted but recognized the limited applicability of alerts
within the EHR and the potential barriers for the accessibility of the prescription. The barrier of
accessibility was overcome by stocking the naloxone within the clinic. Although, the EHR was
not used to provide patient alerts, the team worked with the CAC to imbed order sets to
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dispense naloxone and provide education in an effort to ease time constraints during clinic
visits.
This team-based approach also allowed the facilitation and communication of Kotter’s
fourth step, understanding of goals. Kotter’s fifth step was addressed when an action plan was
developed using the best practice suggested by the DNP student facilitator that would lead to a
demonstration of improved naloxone co-prescribing as evidenced by an increased number of
naloxone prescriptions being distributed.
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Setting/Sample







Intervention(s)

Community
stakeholders
Pharmacy staff
Medical
community



6 safety net
clinics in San
Francisco
111 Providers



Develop evidencebased consensus
statement

Outcomes/Measures







Naloxone co-prescribing
training
Providers received 3
focused follow up
sessions (rationale and
indications for
prescribing naloxone,
available naloxone
formulations, insurance
coverage information
and communication
strategies around
discussing naloxone with
patients)
Email reminders sent to
providers to remind them
about naloxone coprescribing



Findings

3 guiding
principles
developed
1 relevant to
project: promoting
appropriate and
safe use of
prescription
opioids



Engage with providers to
advance the coprescription of naloxone
with prescription opioids

Explore naloxone
co-prescribing in
primary care
setting after
trainings



79.3% of providers who
received the AD session
prescribed naloxone (no
co-prescribing in place
prior to intervention)
99.1% were likely to very
likely prescribe naloxone
in the future
59.8% likely to prescribe
to those receiving low
doses (< 20 MME daily)
83.9% likely to prescribe
to > 65 years old
80.7% likely to prescribe
to those with no overdose
history
73.6% with no SUD
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Setting/Sample




Intervention(s)

40 randomly
selected opioid
prescribing
primary care
providers in the
San Francisco
Area



VA providers
who were
actively treating
patients in
family practice
or substance
use disorder at
time of study





Providers received
detailing regarding
naloxone prescribing for
5-60 minutes
(m = 28 minutes)
Most frequently covered
topics included:
indications for naloxone,
examples of naloxone
prescriptions, language
to use with patients, and
pharmacy outreach
A total of 750 (22.6%)
out of 3,313 providers
received at least one
OEND-specific AD visit

Outcomes/Measures

Findings



Changes in rates
of naloxone
prescriptions,
comparison 4
months before and
after providers
received academic
detailing of
naloxone
prescribing



Naloxone coprescriptions filled by
patients increased from 0
to 10 among those that
had been seen by a
provider who received
detailing vs. by the
providers who did not
receive detailing (IRR =
11.0; 95% CI [1.8, 67.8],
p = 0.010)



Evaluate the
impact of
academic detailing
on naloxone coprescribing



Naloxone co-prescribing
rate (from baseline to 2
years) was 7.1% greater
in the AD exposed
providers (95% CI =
2.0%, 12.5%) compared
to the AD-unexposed
providers

NALOXONE CO-PRESCRIBING

Citation
Coffin et al.
(2016)

Design/Level/
Quality Rating
 Quasiexperimental
 Level II
 Grade A

41

Setting/Sample




6 safety net
clinics in the
San Francisco
area
1985 adults
receiving longterm opioid
therapy for pain

Intervention(s)








Delaney et
al. (2016)





QI project
Level V
Grade B





4 primary care
offices in
western
Connecticut
serving as
medical home
training sites
for primary care
residents
All patients on
chronic opioid
therapy
screened for
eligibility






Outcomes/Measures

Onsite leader selected
Clinic staff received
training in naloxone
prescribing (including
rationale and indications
for prescribing, language
to approach patients,
naloxone formulations
and pharmacy/payor
coverage)
Staff trained how to
educate patients about
naloxone use and
assembly of naloxone
device
Follow up training
provided
At least one reminder
email sent to providers



2-month period
Signage placed in
check-in areas of
patients indicating
naloxone was available
QI safety initiative, those
eligible for naloxone coprescriptions identified
and approached by
residents who were
given scripting for
encounter



Findings

Proportions of
patients
prescribed
naloxone, opioidrelated emergency
visits and
prescribe opioid
dose based on
chart review



Rate of naloxone
co-prescriptions
written







759 (38.2%) of 1985
eligible patients were coprescribed naloxone
during intervention
No net change in opioid
dose over time between
those that received
naloxone prescription
and those who did not
(IRR = 1.03, 95% CI =
0.91-1.27, p = 0.61)

Training sites increased
naloxone co-prescription
rates from 0 to 53 of 204
(26%) eligible patients
3 sites dispensed (n = 3,
N = 64) naloxone
prescriptions, where
opioids were managed by
pain specialists; the 4th
site managed opioids by
the primary care and
dispensed a higher
percentage of naloxone
(n = 50, N = 140)
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Setting/Sample


Multisite
academic
health system
in California

Intervention(s)





Implement a naloxone
distribution program
Staff member were
given trainings lasting 15
minutes to 1 hour that
covered
epidemiology of
overdose, evidence for
naloxone distribution,
methods of naloxone
administration, criteria
for prescribing, EHR
steps for prescribing and
related prescribing and
liability laws
PowerPoint training was
made available to staff
who could not attend

Outcomes/Measures


Rate of naloxone
co-prescriptions
written

Findings







Naloxone prescription
rates increased from 4.5
per month to 46 per
month following full
implementation,
indicating a 10-fold
increase
Physicians wrote 85.3%
(n = 209, N = 245)
NP wrote 9.8% (n = 24, N
= 245)
PA wrote 3.7% (n = 9, N
= 245)
Pharmacists wrote 1.2%
(n = 3, N = 245)
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Setting/Sample


VHA medical
facilities
nationwide (N =
142)

Intervention(s)


Implement OEND
nationwide

Outcomes/Measures





Pharmacy
development of
naloxone rescue
kits
Developing clinical
guidance for
issuing kits
Supporting OEND
as a focal
campaign of AD

Findings













VHA dispensed 45,178
naloxone prescriptions in
2016 by 5693 prescribers
to 39,328 patients
Initial VHA pilots varied in
their training process,
ranging from individual
training by clinical
champion to training of
staff by community
partners and train-thetrainer models.
Recommendations
included:
Have a champion with
dedicated time to support
and facilitate OEND
implementation.
Establish at least one
clinical champion at each
facility to help speed
OEND implementation.
Clinical champion should
work with leadership to
develop OEND
implementation plan
Consider using AD
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Setting/Sample






Large
academic
family medicine
practice in
North Carolina
n = 350 (N =
709) patients
met CDC
criteria for
naloxone
prescribing
n = 12 had
naloxone on
their
medication list
prior to
implementation

Intervention(s)









Develop a targeted
naloxone co-prescribing
program in a primary
care practice through
use of a clinical
champion
Sequential concurrent
three phase rollout:
Phase one: Pharmacists
(clinical champion)
embedded in practice
provided academic
detailing
1. Opioid epidemic
awareness
2. Emergency
management
3. Naloxone
administration
4. Financial
considerations
Phase two: Logistical
barriers to prescribing
naloxone were
addressed
Phase three: Barriers
related to patient
engagement addressed

Outcomes/Measures


Improve naloxone
co-prescriptions
rates

Findings



Program in progress
Article was received for
submission August 31,
2016, program was fully
implemented September
2016. Authors address
that next steps include
determining how many
patients identified
actually received
naloxone prescription.
Assessments planned at
six, twelve and eighteen
months.
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Setting/Sample




Convenience
sample of
prescribers
within the
Veterans
Affairs health
system
n = 45, N = 54

Intervention(s)



Non-interventional
Surveys completed by
prescribing providers to
obtain baseline
knowledge and concerns
prior to attending OEND
education training

Outcomes/Measures






Determine how
knowledgeable
and comfortable
are providers
regarding the
clinical
incorporation of
OEND
Determine if
providers have
concerns, what is
their nature and
magnitude?
Determine if
knowledge or
concern vary by
practice setting
and profession.

Findings




Concerns of iatrogenic
effects of OEND were
rated higher than
concerns about
impressions of unsafe
prescribing practices
(t(42) = 3.06, p < .01)
Endorsement of lack of
knowledge/familiarity/com
fort (t(42) = 3.91, p <
.001)
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CHAPTER 3
IMPLEMENTATION OF PRACTICE CHANGE
Naloxone co-prescriptions are recommended as a risk mitigation strategy in opioid
prescribing, yet there is still a nationwide struggle to gain acceptability of universal prescribing in
primary care settings (CDC, 2016a). Despite recommendations by governing bodies and
agencies targeting the opioid epidemic, there remains a wide gap between naloxone coprescriptions practices and provider adherence to guidelines (CDC, 2016a; IHS, 2015;
USDHHS, 2016)
Participants and Setting
The focus of this DNP project was to implement a multifaceted intervention, which
included an academic detailing program, provider reminders, and the utilization of a clinical
champion, to improve rates of naloxone co-prescribing within a primary care setting. The
project was initiated among an Indian Health Service Tribal Health Department with one
satellite locations in a rural setting and one an urban setting; these facilities will furthermore be
referred to as Clinic X. A third satellite location, within an occupational setting, was not included
in the project data as that facility typically did not see a patient population which received
chronic opioids, and the DNP student facilitator was also the primary provider at that location.
Thus, excluding patients seen at this venue removed the potential selection bias that may have
skewed outcome data in this EBP project.
While in separate geographic locations, the clinics had attempted to standardize practice
across the settings and utilize evidence-based medicine whenever possible. Although clinic
providers typically remained stationed at one location, all were cross-trained to work in any of
the settings. Many of the support staff and other departments worked among all the clinics on a
routine basis.
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Within the Indian Health Services Tribal Health Department, the governing tribal council
had deemed the opioid epidemic a priority and implemented a policy to assist with the
distribution of naloxone to at-risk tribal members and clinic utilizers. Despite this, the tribal
health department providers had vocalized concerns at regularly scheduled staff meetings
regarding current best-practice evidence for both opioid prescribing and naloxone distribution.
A recently revised mission statement which focused on quality, integrated patient centered-care
prompted the review of current prescribing practices to determine if what was presently utilized
was in fact, current best practice.
Offering a wide variety of primary care services including pain management, the clinics
were well-appointed to determine if a multi-faceted approach would increase naloxone coprescriptions to patients who were prescribed long-term (30 days or longer) opioid medications.
The clinics were staffed by providers of a variety of health care disciplines, with prescribing
providers including one full-time PA in the rural location, one full-time PA in the urban location,
one NP (DNP student facilitator) in the occupational setting and two physicians: one working
full-time and rotating through each clinic location and the medical director who works one day
per week, rotating clinical sites. The medical director provided oversight to the advanced
practice clinicians and assisted with complex patient management, including those who were
prescribed controlled substances. Aligning well with the Iowa model, in a team format, all
providers verbally gave support to proceed with a project that would assist with furthering the
goal of safe opioid prescribing and management.
Pre-Implementation Data
Clinic X provided services to 48 eligible patients receiving chronic opioid prescriptions
(30 days or longer) between September 25th, 2016 through December 15th, 2017. None of
these patients were found to have received a naloxone prescription during this period. Nearly
two-thirds of these patients were females (66.7%, n = 32) and the remaining 16 patients being
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males (33.3%). The slight majority of patient were seen in the urban clinic (58.3%, n = 28),
while the rural clinic provided services to the other 41.7% (n = 20).

Outcomes
This EBP project examined how a multifaceted intervention, utilizing a clinical champion
who provided an academic detailing session and intermittent formal and informal follow-up
(provider reminders) to the prescribing providers could influence naloxone co-prescriptions.
Additionally, during the primary formal academic detailing session, printed materials were
distributed. The printed materials served two purposed: (a) references for prescribing providers
and (a) educational tools to be distributed to patients during clinic encounters. The primary
outcome of the EBP project was to measure the rates of naloxone co-prescriptions written to
eligible clinic utilizers by primary care providers within the health care clinics during a 12-week
period. Literature supported the use of a clinical champion to advocate for the use of naloxone
co-prescriptions and provide the academic detailing session (Behar et al., 2016; Behar et al.,
2017; Bounthavong et al., 2017; Coffin et al., 2016; Delaney et al., 2016; Devries et al., 2017;
Oliva et al., 2017; Wilson et al., 2017; Winograd et al., 2017). Twelve weeks of preimplementation data were collected via retrospective chart review, for those patients who had
received opioid prescriptions of 30 days or greater, from the corresponding period the year prior.
Evaluating data from the same period the previous year helped to eliminate seasonal
fluctuations of clinic usage and to prevent any prescribing practice changes that providers may
have self-initiated during the planning stages of this DNP project. This data was then compared
to prescribing patterns twelve weeks during the implementation phase, a length chosen
purposefully to align with recommendations from the CDC that patients receiving chronic opioids
be re-evaluated every three months (CDC, 2016a). This time frame provided the best scenario
for being able to capture all eligible chronic opioid users during the intervention period. For
comparison of naloxone co-prescription rates collected during the pre-implementation phase
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and implementation phase, chi-square analysis was utilized. Based on evidence demonstrated
from Delaney et al. (2016), a benchmark outcome of a 25% increase in naloxone co-prescribing
rates would indicate project success. Additionally, secondary analyses investigated
relationships between patient demographics, provider adoption of co-prescribing, daily MME
prescribed, concurrent benzodiazepine use, clinic location, and whether a clinic visit occurred
for any reason during the data collection period.
Planning and Intervention
The implementation of the practice change and data collection was conducted over
twelve weeks, from September 25, 2017 to December 15, 2017. Consistent with Kotter’s eightstep change theory, support from the clinical agency and key stakeholders was obtained early in
the planning stages. The clinical manager and prescribing providers contributed to the plan and
provided verbal encouragement to the DNP student facilitator. As planning proceeded, the
project was divided into three phases. The first phase being the pre-implementation phase
where the DNP student facilitator collected data, procured educational materials, and developed
the academic detailing session. The second phase consisted of the implementation of the
intervention, which included the presentation of the formal academic detailing session and
clinical champion involvement. The third and final phase consisted of post-intervention data
collection and analysis.
Following the approval of the IRB board from Valparaiso University, implementation and
coordinating data collection began September 25, 2017. A large portion of the preparatory work
was completed by the DNP student facilitator via unpaid hours that also satisfied DNP program
course requirements. Development of the instrument design for data collection (Appendix A), a
one-hour academic detailing session PowerPoint (Appendix B), provider naloxone prescribing
guide (Appendix C), and patient naloxone educational pamphlet design (Appendix D), as well as
procurement of educational posters (Appendix E) and adding the naloxone into the EHR for
documentation of distribution in the clinic were all completed prior to implementation.
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Additionally, with the assistance of the Clinical Applications Coordinator (CAC), an employee of
the agency who assists providers and other clinic staff to optimize the utilization of the EHR and
create, run, and distribution various reports in her normal job duties, baseline data of all current
chronic opioid patients was obtained and reviewed for accuracy, which was later distributed to
the appropriate ordering provider during the formal academic detailing session. Consistent with
Kotter’s short-term wins, the clinical champion provided project updates and status of naloxone
distribution at regularly scheduled monthly provider meetings, planned email update at the midway point and other informal individual contacts via phone, email, video conference and face-toface interactions. The DNP student facilitator made efforts to ensure informal contacts occurred
equally among prescribing providers so that naloxone adoption rates would not be influenced.
During the implementation phase, the providers, the registered nurse (RN) clinical
manager, and the clinical support staff; consisting of two full time RNs and two full time medical
assistants (MA), were provided the academic detailing session regarding naloxone coprescriptions during two separate sessions on September 25th and September 26th, 2017.
Although originally planned to take place in a single session, so all members of the CS task
force could be present, a scheduling conflict arose, and the session was therefore repeated the
following day to capture those previously unable to attend. The 1-hour session, conducted in
the health department conference room at the rural location with simultaneous videoconferencing to the urban location, consisted of a PowerPoint presentation adapted from
educational materials previously developed by PrescribeToPrevent, a nationally recognized
organization that published toolkits regarding opioid safety and overdose prevention resources
for prescribers and pharmacists (PrescribeToPrevent, 2015). The publications were widely
available on the internet and were free for use. During this session, the following topics were
addressed: (a) relevant opioid overdose statistics, (b) naloxone pharmacology, (c) current
naloxone co-prescribing recommendations, (d) current organizational naloxone policy (which
included stocking naloxone onsite and dispensing the medication prescribed the day of the
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office visit versus returning for the for the education component), (e) proper naloxone
administration (via a 7-minute video [an organizational policy requirement for patients being
distributed naloxone]), and (f) procedures for EHR documentation. A packet containing a copy
of the PowerPoint slides (Appendix B), the current CDC prescribing clinician pocket reference
(Appendix F), naloxone product comparison sheet (Appendix G), a fact sheet from the
manufacturer of the naloxone product purchased for distribution (Appendix H), and a quick start
guide for the same naloxone product (Appendix I) were provided to all participants. Additionally,
each prescribing provider received an individualized report compiled by the CAC that listed all
patients who had received an opioid, benzodiazepine, or naloxone prescription in the 90 days
preceding the academic detailing session.
The providers were advised to begin utilizing universal naloxone co-prescribing practices
immediately and were encouraged to use the CAC provided list of their patients as a reference
to capture those patients during any clinic visit that occurred during the intervention period,
whether for an opioid related reason or for another reason, such as acute illness. The DNP
student facilitator was available throughout the implementation period for support or additional
academic detailing as needed, which arose only as simple clarification questions regarding the
distribution process, not the pharmacology or rationale for naloxone co-prescribing. Consistent
with Kotter’s short-term wins, a follow up email was sent by the clinical champion at the 6-week
mark to remind providers of the ongoing intervention and to inform providers of interim data,
including the number of prescribed naloxone dispensed thus far; this reminder intended to
provide further motivation and prevent stagnation of the EBP project intervention. The
intervention was also discussed at the monthly provider meetings, providing another opportunity
to discuss short-term wins (such as distribution success) and any provider concerns and
barriers were addressed at that time.
Clinical support staff, who also attended the academic detailing session, were
responsible for the management of a naloxone distribution log as per organizational policy
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(maintained in an electronic fob access formulary at each location). Access was only available
to providers, clinical support staff, and the clinical manager. Support staff were also responsible
for maintaining the supply of naloxone and reordering if stock became low. Replacement stock
generally arrived one business day after the order was placed.
Posters obtained from PrescribeToPrevent.org (2015) (Appendix E) were placed in
targeted vantage point locations of the waiting area, restrooms, and exam rooms. Additional
information regarding the availability of naloxone at the clinic was included in an educational
article written by the DNP student facilitator, published in the quarterly health publication, fall
edition (Appendix J). This publication was mailed to the homes of all current registered patients
of the clinic and additional copies were widely available throughout the clinics in the waiting
areas and exam rooms. The original intention for these materials were for patient education;
however, during the EBP project, they also served as visual reminders to the prescribing
providers.
During the post-implementation phase, the DNP student facilitator calculated the
outcomes measures, including the primary objective: naloxone co-prescription rate differences
between the pre-intervention period and the intervention period. Since the pre-intervention
group was known not to have dispensed any naloxone co-prescriptions, secondary statistics
were calculated solely on the intervention group. To determine if relationships existed in the
intervention group, demographics (including age, gender, daily MME, concurrent prescription of
benzodiazepines clinic location and provider discipline) were evaluated.
Data
Collection
At the completion of the 12-week implementation period, a chart audit was conducted to
determine the percentage of eligible patients prescribed naloxone. This was done with the
assistance of the CAC, who, within her usual job duties, generated reports from the Resource
and Patient Management System EHR used by the clinics. Reports regarding co-prescriptions
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of naloxone as well as current opioid prescriptions written were then verified by the DNP student
facilitator for accuracy and cross-referenced with the naloxone distribution log maintained by the
clinical support staff to ensure complete data capture. Based on the reports generated by the
CAC, 48 EHR records were audited pre-implementation and 40 EHR records were audited from
the implementation period. Demographics regarding mean age, gender, primary diagnosis,
tribal affiliation, concurrent benzodiazepine prescriptions, and daily MME of opioid dosing were
also collected to evaluate if there were any differences in the proportion of naloxone coprescriptions written based on these characteristics. Additionally, whether the patient had a
clinic visit during the intervention period, which clinic dispensed the naloxone, which provider
dispensed, and whether the dispensed naloxone was recorded in the EHR correctly were further
evaluated.
Informal bi-weekly review of the naloxone distribution log afforded the opportunity for
continuous evaluation of study implementation. This was provided by either a verbal report from
the clinical support staff in each clinic or a visual review by the DNP student facilitator.
Management and Analysis
SPSS Version 22 was utilized for data analysis. Parametric statistics were conducted to
test that providing academic detailing sessions via a clinical champion was associated with an
increased rate of naloxone co-prescriptions dispensed within a primary care clinic setting. In an
effort to determine if further relationships existed in the intervention group, additional parametric
and non-parametric testing was completed to evaluate statistical differences.
Protection of Human Subjects
The student facilitator successfully completed the National Institutes of Health (NIH)
protection of human rights training on February 28th, 2017 (Appendix K). To protect human
rights and maintain compliance with HIPAA laws, identifying information (e.g., patient name and
medical record number) was kept within the clinical setting and security was maintained in a
locked cabinet, accessible only by the DNP student facilitator. The naloxone distribution log, as
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per organization policy was securely maintained in an electronic fob access formulary which
itself was located inside the providers’ office. Electronic fob access was available only to the
providers, clinical support staff, and clinical manager. The office space itself was locked when
not occupied by a provider. During chart audits, EHR records accessible to the DNP student
facilitator through authorization of her employment status, were conducted in the facilitator’s
closed office when other staff members were not present, to ensure that protection of data was
maintained. No identifying data of individual patients was disclosed during the final report, as
project data was reported in the aggregate form only. The student facilitator will maintain the
records in this secure fashion for three years, at which time data will be destroyed by shredding.
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CHAPTER 4
FINDINGS
This EBP project was designed to determine the effect of a multi-faceted intervention on
the naloxone co-prescription rates among primary care providers, who prescribed chronic
opioids to patients for 30 days or greater, in a tribal health clinic. The PICOT question posed
was: Among primary care providers in a tribal health clinic, does the introduction of an evidencebased multi-faceted intervention versus the current practice of no tool, improve the coprescription rates of naloxone to chronic opioid patients within a 12-week period? The project
was conducted in two Indian Health Service clinics in Southwest Michigan, one rurally located,
the other within an urban setting. While each location had a primary, full-time advanced
practice clinician, both of which were PAs, two additional providers, a full-time staff physician
and a part-time physician medical director, rotated to all the clinics operated by the tribal
government. All providers had been cross-trained to work at each location. The multi-faceted
intervention consisted of provider education provided during a one-hour discussion and
PowerPoint academic detailing session, the utilization of a clinical champion (DNP student
facilitator), and posters placed strategically throughout the clinic (waiting room, exam rooms and
bathrooms), which served the dual purpose of visual reminders to the providers and provided
education to the patients.
Data collected from a retrospective chart review during a 12-week intervention period
was compared to the correlating 12-week time period the previous calendar year and manually
entered into the Statistical Package for the Social Services (SPSS) for statistical analysis.
Testing was performed to answer the following primary question:
Question one: What are the naloxone co-prescription rates and are they significantly different
between the two project periods?
Statistical analyses also evaluated secondary questions:
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Question two: Does patient age influence the likelihood of dispensing a naloxone coprescription?
Question three: Does patient gender influence the likelihood of dispensing a naloxone coprescription?
Question four: Does the amount of daily MME influence the likelihood of dispensing a naloxone
co-prescription?
Question five: Does the concurrent prescription of benzodiazepines influence the likelihood of
dispensing a naloxone co-prescription?
Question six: Does the clinic location influence the likelihood of dispensing a naloxone coprescription?
Question seven: Does the provider discipline (PA or physician) influence the likelihood of
dispensing a naloxone co-prescription?
Participants
Physician one had over 20 years of clinical experience and had been working with the
tribal clinic for approximately four years. This part-time physician serves as the medical director
of the clinics, rotating between sites on a weekly basis. Physician two had over 25 years of
clinical experience and worked full time, alternating between the rural and urban clinics.
Physician two had been employed by the tribe for the past three years, but on a part-time basis
until the past year. PA one had nearly 30 years of clinical experience and had been employed
by the tribal clinic for approximately six years, working from the rural location. The final
provider, PA two, was the most recent to join the staff, having approximately three years of
clinical experience and working for the tribal clinic in the urban location for the past two years.
Clinic patients were eligible to receive a naloxone co-prescription from the provider
during the EBP project if they were a federally recognized tribal member, spouse of a tribal
member, or otherwise eligible to be seen at either clinic location as an employee of the Tribal
Government. Additionally, eligible patients were ages 18 and above, non-pregnant, and
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receiving an opioid prescription (of any MME equivalents) of 30 days or greater during the EBP
project.
Consistent with Kotter’s model and the team-based approach, patients were considered
eligible for inclusion regardless of a medical visit occurring during the 12-week intervention.
Since the clinics offer services across several healthcare modalities, eligible patients may have
been physically present at the clinic during the intervention either accessing another service or
presenting to pick up a physical prescription for the opioid medication. Therefore, team
members had opportunities unique to this setting to offer naloxone co-prescriptions outside of a
traditional medical clinic visit.
Size and Characteristics
Pre-Intervention Group Characteristics. A retrospective chart audit of patients’
medical records was conducted to collect baseline data. Data was compiled from 48 medical
records of patients who received a 30-day or greater prescription of opioids in the 12-week
period dating September 25th, 2016 to December 15th, 2016. The chart audit consisted of
patients ranging in ages from 26 to 72 years. The mean age was 50.0 years (SD = 10.46). Of
the group, 33.3% (n = 16) were male and 66.7% (n = 32) were female. The majority of the
patients, 56.3% were of ‘other tribal affiliation” (n = 27), members of the tribal affiliation which
funds the clinics constituted 41.7% (n = 27) of the audited charts; patients in the remainder
2.1% of audited charts were categorized as “non-tribal affiliation” (n = 1). During the 12-week
audit period, 75% (n = 36) of the patients did have a clinic visit occur, while the remainder did
not. The majority of eligible patients were patients of the urban location, 58.3% (n = 28); while
the remaining patients, 41.7% (n = 20) were patients at the rural location. Prescribing provider
discipline was equally split among patients with PAs and physicians, each writing 50% (n = 24)
of the opioid prescriptions in the audit period. The mean daily MME was 24.6 (SD = 18.37) with
a range of 5 to 95 MME. Additionally, 8 (16.7%) of the patients received a benzodiazepine
prescription in addition to their opioid prescription (see Table 4.1).
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Intervention Group Characteristics. Data was collected from a total of 40 patients
who obtained an opioid prescription of 30 days or greater during the 12-week intervention period
that occurred between September 25th through December 15th, 2017. The patients were similar
in age to the pre-intervention group, ranging from 29 to 70 years old with a mean age of 49.9
years (SD = 10.44). The intervention group, however, did have a higher percentage of females,
72.5% (n = 29) than the previous group. Accordingly, the percentage of male patients was less
(27.5%, n = 11). Membership of the tribe which funds the clinic was 37.5% (n = 15), non-tribal
affiliated patients accounted for 10% (n = 4) of the opioid prescriptions, and the majority of the
patients receiving opioids were of other tribal affiliations (52.5%, n = 21). The overwhelming
majority of the patients, 37 (92.5%) did have a visit during the intervention time frame, while only
the remaining three did not (7.5%). As noted with the pre-intervention group, the urban located
clinic was the source of the majority of the patients receiving an opioid prescription 65% (n =
26), while the remaining 35% (n = 14) were patients at the rurally located clinic. A physician
was the prescribing provider for 55% (n = 22) of patients receiving an opioid during the
intervention period, while 45% (n = 18) of the patients were prescribed by the PAs. Daily MME
among opioids prescribed ranged from 2.5 to 172.5, with a mean of 24.16 (SD = 30.96). Only
22.5% (n = 9) patients in the group received a concurrent benzodiazepine prescription, while the
remaining 77.5% (n = 31) did not (see Table 4.1).
Changes in Outcomes
Statistical Testing and Significance
Using SPSS Version 22 for analysis, parametric tests were run to compare the naloxone
co-prescription rates between the two groups: pre-intervention (N = 48) and intervention (N =
40). Statistical significance for all data was established as p < .05. A chi-square test of
independence was calculated to analyze the association between the use of a multi-faceted
intervention and naloxone co-prescription rates. Secondary variables of interest were
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calculated within the post-intervention group utilizing chi-square analyses and independent
samples t testing.
Findings
Primary outcome.
Question one: What are the naloxone co-prescription rates and are they
significantly different between the two project periods? During the pre-intervention group,
there were no naloxone co-prescriptions distributed (0 of 48 eligible patients) while 10 of the 40
eligible patients within intervention group (25%; X2 = 13.538, p <.001) had naloxone distributed
(see Figure 4.1). Additionally, all 10 of the patients who received the naloxone co-prescription,
did have a clinic visit occur during the intervention period. A further demographic breakdown of
those who received naloxone and those who did not is available in Table 4.2.
Secondary outcomes.
Secondary descriptive statistics were calculated within the post-intervention group to
evaluate if further relationships existed. Parametric and non-parametric tests were utilized as
appropriate. None of the secondary variables of interest, except patient gender, were found to
affect naloxone distribution.
Question two: Does patient age influence the likelihood of dispensing a naloxone
co-prescription? An independent-samples t test comparing the mean ages of patients which
received naloxone co-prescriptions against those who did not. The mean age of people who
received naloxone (M = 50.5) was not significantly different from the mean age of those who did
not. (M = 49.7; t = 0.207, p = .837).
Question three: Does patient gender influence the likelihood of dispensing a
naloxone co-prescription? In the intervention group, 11 male patients and 29 female patients
were eligible to receive a naloxone co-prescription (see Figure 4.2). However, none of the
eligible males received one, while 10 (34.4%) of the 29 eligible females did (X2 = 5.057, p =
.025).
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Question four: Does the amount of daily MME influence the likelihood of
dispensing a naloxone co-prescription? Review of the data indicated that there was a wide
range in the daily MME patients who had been co-prescribed naloxone, ranging from 10 to
172.5 daily MME. Patients in the intervention group who did not receive a naloxone coprescription had daily MME ranging from 2.5 to 95. The mean daily MME of the patients who
received naloxone co-prescriptions (M = 39.68) did not significantly differ from eligible patients
who were not prescribed naloxone (M = 22.99; t = 1.500, p = .142).
Question five: Does the concurrent prescription of benzodiazepines influence the
likelihood of dispensing a naloxone co-prescription? Within the intervention group, nine of
the 40 patients (22.5%) had a concurrent benzodiazepine prescription, one of the additional risk
factors for opioid overdose potential. Of the 10 patients who received a naloxone coprescription, 30% (3 patients) were concurrently receiving a benzodiazepine prescription. No
statistically significant relationship was found (X2 = .430, p = .512).
Question six: Does the clinic location influence the likelihood of dispensing a
naloxone co-prescription? Since each of the clinics served a unique population due to the
contrasting urban and rural populations, naloxone co-prescriptions between locations was also
evaluated. The rural clinic serviced 35% (n = 14) of the eligible patients while the urban clinic
serviced the remaining 65% (n = 26). As mentioned previously, naloxone co-prescriptions were
dispensed ten of the total eligible 40 patients. Of the ten, two (20%) were the rural patients and
eight (80%) were the urban patients. Although the urban setting had a 4:1 ratio over the rural
setting, clinic location did not appear to be a statistically significant factor in naloxone coprescription rates (X2 = 1.319, p = .251).
Question seven: Does the provider discipline (PA or physician) influence the likelihood
of dispensing a naloxone co-prescription? Finally, comparisons between disciplines was
conducted. While each of the PAs were stationed primarily at one clinic, both the full-time and
part-time physician rotated among the clinics. Interestingly, the physicians prescribed the
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majority, 70% (n = 7) of the naloxone co-prescriptions, while the PAs prescribed 30% (n = 3).
However, the physicians also saw a slight majority, 55% (n = 22), of the eligible patients in the
intervention phase. Provider discipline did not appear to be a factor in naloxone co-prescription
rates (X2 = 1.212, p = .271). A further breakdown of provider dispensing patterns in located is
Table 4.3.
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Table 4.1
Group Characteristics
Pre-Intervention

Intervention

Gender

Frequency

Percentage

Frequency

Percentage

Male

16

33.3%

11

27.5%

Female

32

66.7%

29

72.5%

Funding Tribe

20

41.7%

15

37.5%

Other Tribe

27

56.3%

21

52.5%

Non-Tribal

1

2.1%

4

10.0%

Rural

20

41.7%

14

35.0%

Urban

28

58.3%

26

65.0%

Tribal Affiliation

Clinic Location

Clinic Visit During Audit Period
Yes

36

75.0%

37

92.5%

No

12

25.0%

3

7.5%

Concurrent Benzodiazepine Prescription
Yes

8

16.7%

9

22.5%

No

40

83.3%

31

77.5%
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Table 4.2
Intervention Group Characteristics
Naloxone

No Naloxone

Gender

Frequency

Percentage

Frequency

Percentage

Male

0

0%

11

36.7%

Female

10

100%

19

63.3%

Funding Tribe

1

10%

14

46.7%

Other Tribe

9

90%

12

40%

Non-Tribal

0

0%

4

13.3%

Rural

2

20%

12

40%

Urban

8

80%

18

60%

Tribal Affiliation

Clinic Location

Clinic Visit During Audit Period
Yes

10

100%

27

90%

No

0

0%

3

10%

Concurrent Benzodiazepine Prescription
Yes

3

30%

16

20%

No

7

70%

24

80%
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Table 4.3
Naloxone Co-Prescriptions Dispensed by Provider Type
Physician 1

Physician 2

PA 1

PA 2

Naloxone Prescribed - Yes

1

6

2

1

Naloxone Prescribed - No

1

14

11

4

Clinic Location (Rural/Urban)

0/2

1/19

13/0

0/5

Total Eligible Patients

2

20

13

5

50%

30%

18.18%

20%

5%

50%

32.5%

12.5%

Adoption/Co-Prescribing % Per
Provider
Adoption/Co-Prescribing %
Within the Organization

NALOXONE CO-PRESCRIBING
Figure 4.1
Improvement in Naloxone Co-Prescription Rates
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CHAPTER 5
DISCUSSION
This EBP project was designed to answer the PICOT question: “Among primary care
providers in a tribal health clinic, does the introduction of an evidence-based multi-faceted
intervention versus the current practice of no tool, improve the co-prescription rates of naloxone
to chronic opioid patients within a 12-week period?” This project, which was implemented at
two clinics located in the Midwest within an Indian Health Services Health Department, sought
to determine if a multi-faceted intervention, which included an academic detailing session, the
use of a clinical champion and visual reminders, influenced the behavior of providers to increase
naloxone co-prescription rates. An explanation of project findings, along with examination of
key factors that contributed to success and project limitations, will be discussed in this chapter.
Additionally, evaluation of theoretical and EBP framework utilized to guide this project and
implications for future projects of this nature will also be detailed.
Explanation of Findings
Although the naloxone distribution policy from which this project was initially conceived,
was part a larger organizational policy, logistical implementation and acceptance was left up to
the individual departments of the organization. The evaluation plan for this EBP project was
directed to answer the primary outcome question, but also was intentionally designed to
evaluate secondary outcomes in an effort to guide future naloxone co-prescription practices.
Question one: What are the naloxone co-prescription rates and are they significantly
different between the two project periods? As the primary outcome for this project, the majority
of focus was placed on this particular query. Initially, zero naloxone prescriptions had been
distributed in the pre-intervention stage (n = 0, N = 48). The pre-intervention period data was
procured via a retrospective chart audit of eligible patients who obtained an opioid prescription
of 30 days or greater during the time period of September 25th, 2016 to December 15th, 2016.

NALOXONE CO-PRESCRIBING

68

This data was then manually reviewed to ensure accuracy and quantified using an audit sheet
developed by the DNP student facilitator. The audit processes were repeated for the 12-week
period that followed the prescribing providers’ AD session and distribution of educational
materials by the clinical champion (September 25th to December 15th, 2017). Initially, the timing
of the project was scheduled to coincide with the purchase and delivery of naloxone stock and
availability of providers to attend the AD session; however, a delay in the naloxone stock
delivery, caused the product to be unavailable for physical distribution within the clinic setting for
the first 10 days of the project intervention period. Thus, providers initially had to write a
prescription to be filled by the patient elsewhere. Of the 40 possible eligible patients receiving
an opioid prescription of 30 days or greater during the intervention period, 25% (n = 10) were
given a naloxone prescription, a statistically significant increase (X2 = 13.538, p <.001). The
increased percentage of co-prescriptions written for eligible patients was congruent with the
supportive evidence reviewed for this EBP project (Behar et al., 2017; Bounthavong et al., 2017;
Coffin et al., 2016; Delaney et al., 2016; Devries et al., 2017).
Additional secondary outcomes were evaluated based solely on data from the
implementation period since no naloxone co-prescriptions had been given pre-implementation.
To evaluate if any further relationships existed, additional parametric and non-parametric testing
was completed to determine statistical significance.
Question two: Does patient age influence the likelihood of dispensing a naloxone coprescription? Previous literature indicated that providers were more likely to prescribe naloxone
to patients who were older (Behar et al., 2016). However, within this EBP project, the age of
those who received naloxone (M = 50.5) was similar to those who did not (M = 49.7); therefore,
a statistical relationship relating to age was not established (t = 0.207, p = .837).
Question three: Does patient gender influence the likelihood of dispensing a naloxone
co-prescription? While male patients represented 27.5% of those eligible for the coprescription, none received the naloxone. Females accounted for the remaining 72.5% of the
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population and were the recipients of 100% of the naloxone distributed during the project.
Although none of the supportive evidence reviewed for this project indicated gender bias in coprescribing, the difference in co-prescribing among gender within this project did achieve
statistical significance (X2 = 5.057, p = .025).
Question four: Does the amount of daily MME influence the likelihood of dispensing a
naloxone co-prescription? Behar (2016) discussed that prescribing providers were to utilize
naloxone co-prescriptions among either subgroup of patients prescribed high (> 20 MME) or low
dose (< 20 MME). Among the patients seen during the intervention period, there was a wide
range in the daily MME amount (2.5 to 172.5, M = 24.16, SD = 30.96). Contrasting Behar’s
findings, those that received naloxone, did have a higher MME amount (M = 39.68) than those
who did not (M = 22.99), the difference among these groups could be attributed to the small
population size and the inclusion of one outlier who had a daily MME of 172.5 (one of the
naloxone recipients). This postulation was further supported when statistical significance was
not established regarding prescribing patterns related to daily MME (t = 1.500, p = .142).
Question five: Does the concurrent prescription of benzodiazepines influence the
likelihood of dispensing a naloxone co-prescription? Guidelines indicate that concurrent use of
benzodiazepines are a risk factor for increased opioid overdose potential, and this was an issue
that was discussed during the AD session conducted by the clinical champion (Alexander et al.,
2015; CDC, 2016a; Duvivier et al., 2017; USDHHS, 2016). When the providers were provided
their individual list of patients currently receiving opioid prescriptions, concurrent
benzodiazepine prescriptions included. Although 30% (n = 3) of the 10 patients receiving a
naloxone co-prescription were found to be also on a benzodiazepine prescription, overall 22.5%
(n = 9) of those seen during the implementation period (N = 40) were concurrently receiving a
benzodiazepine. This did not indicate statistical significance in regard to naloxone coprescribing practices (X2 = .430, p = .512).
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Question six: Does the clinic location influence the likelihood of dispensing a naloxone
co-prescription? Early community distribution programs for naloxone have focused on urban
populations, and current literature appears to maintain much of the same focus (Behar et al.,
2016; Behar et al., 2017; Binswanger et al., 2015; Bounthavong et al., 2017; Coffin et al., 2016;
Delaney et al., 2016; Devries et al., 2017; Mueller et al., 2015; Wilson et al., 2017; Winograd et
al., 2017). However, the CDC (2016b & 2016c) has indicated that both rural and urban
populations are affected by opioid overdose and are in need of intervention. Naloxone coprescriptions were dispensed to 10 of the total eligible 40 patients. Of those 10, two (20%) were
rural patients and eight (80%) were urban patients. While the urban setting in this EBP project
dispensed naloxone prescriptions at a 4:1 ratio over the rural setting, this difference was not
statistically significant (X2 = 1.319, p = .251).
Question seven: Does the provider discipline (PA or physician) influence the likelihood of
dispensing a naloxone co-prescription? While the DNP student facilitator was the EBP project
leader and clinical champion, she was also the only nurse practitioner within the practice,
stationed at a third location of the organization, which due to its focus on acute care visits, did
not typically see patients who would meet project inclusion criteria. Therefore, the DNP student
facilitator postulated that the other advanced practice clinicians (PAs) may be more open to
adoption of the naloxone co-prescribing intervention since they had an educational attainment
level similar to the clinical champion. It was also postulated that since both of the PAs were
stationed full time in a single clinic, they would take more ownership of eligible patients and thus
have higher naloxone co-prescribing adoption levels when compared with the full time MD and
part-time MD who rotated between each of the clinics. However, during the intervention period,
physicians saw 55% of the eligible patients (n = 22, N = 40) and prescribed 70% of the naloxone
(n = 7, N = 10). Ultimately, this correlation also did not achieve statistical significance (X2 =
1.212, p = .271).
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Evaluation of Applicability of Theoretical and EBP Frameworks
To guide this project systematically, both a theoretical framework (Kotter’s Model of
Change) and an EBP framework (the Iowa Model of Evidence-Based Practice to Promote
Quality Care) were utilized. The applicability of both will be discussed further below.
Theoretical Framework
The Model of Change, developed by John Kotter has provided a linear approach to
behavioral change in an organization (Melnyk & Fineout-Overholt, 2015). While the project
facility was smaller in size than others in similar projects (Behar et al., 2016; Behar et al., 2017;
Bounthavong et al., 2017; Coffin et al., 2016; Delaney et al., 2016; Devries et al., 2017; Oliva et
al., 2017; Wilson et al., 2017), numerous organizational obstacles still needed to be addressed
to ensure project success; thus, Kotter’s model was well suited to this EBP project.
Kotter’s first step, establishing a sense of urgency, was instrumental for obtaining the
support and cooperation of those involved with the change process. Much of this step was
initiated prior to the development of this EBP project. Due to a heightened awareness created
by national media coverage, the recent tribal health survey, and the ability to attend various
seminars and webinars by both management and clinical staff, support for the project was
garnered. Organizational leaders were aware of the opioid epidemic and thus had drafted a
policy for naloxone distribution, but clinically this had not been implemented due to lack of
process and procedures. The top-down approach of recognition and acknowledgement of the
clinical problem was the catalyst for this project.
The second step was to create a powerful guiding coalition. With the support of upper
level organizational leadership and health department management, a clinical team was
assembled to determine how to best implement the naloxone distribution policy and ensure safe
opioid prescribing practices. While initially this team included the prescribing providers and RN
clinical manager, it was later expanded to include members of behavioral health and other
clinical support staff. Working on projects in a team-based format was familiar to the invested
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parties and was further supported by utilizing Kotter’s model. As the timing of these initial first
steps coincided with the DNP student facilitator’s educational plan for an EBP project, it became
an obvious and unanimous decision for the DNP student facilitator to lead the group and direct
the project. Further support of the project was realized when management, recognizing the
sense of urgency, (a) allowed team members to block schedules to attend meetings, (b)
supported the DNP student facilitator’s use of available work resources (i.e., computer, internet,
printer, and copier), and (c) permitted the DNP student facilitator to work on the project during
periods of decreased patient down time.
Consistent with Kotter’s third step of developing a vision, the assembled clinical team
determined that they would like to pilot an evidenced-based method to distribute naloxone to
current clinic patients as another positive step in their efforts to enhance safe opioid prescribing
practices. As organizational leadership had already developed and approved a general policy
that supported naloxone distribution to anyone who accessed clinic services, the team needed
to further refine that vision and develop a strategy which would garner widespread support.
Thus, after review of literature and synthesis of available evidence, it was envisioned that all
clinic patients who received opioid prescriptions of 30 days or greater would be co-prescribed
naloxone.
While the prescribing providers and RN clinical manager had been supportive of the
project from inception, it was recognized that discussion of opioid overdose prevention
strategies could be an uncomfortable topic for others; therefore, it was imperative to develop a
clear strategy to complete Kotter’s fourth step: communicating the vision. Team members
sought to include ways to decrease barriers and misconceptions regarding the distribution of
naloxone for potential administration by lay persons. To address the issue among clinic staff,
some with medical knowledge and some without, a brief naloxone detailing session was
provided by the DNP student facilitator during a health staff meeting. The session afforded an
opportunity to communicate the vision of the project and aided in eliminating preconceived
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negative ideas or thoughts regarding naloxone. Questions were welcomed and addressed in
the group setting and a further opportunity to address any other questions or concerns in private
was also provided. This academic detailing was duplicated at a more in-depth session for
behavioral health staff who, coincidentally, began distributing naloxone to their own at-risk
clients during the same time period. To communicate the vision of naloxone distribution and
eliminate potential misconceptions of naloxone, further communication to patients and clients
was conducted via written and pictorial methods, as well as one-on-one discussions. To
achieve this, a brief article, written in layman’s terminology, was authored by the DNP student
facilitator, and included within the quarterly health publication that was distributed to all patients
and clients who accessed the health department (Appendix J). Additionally, 8.5” x 11” posters
from prescribetoprevent.org (Appendix E) were obtained, printed, and placed in the waiting
areas, the backs of restroom doors, and in examination rooms.
Kotter’s fifth step has focused on empowering others to act on the vision. To accomplish
this, the team decided that including clinical staff in the AD session and giving them access to
the naloxone stock would be beneficial. While the intended outcome of this EBP project was to
improve naloxone co-prescribing rates among those receiving opioid prescriptions of 30 days or
greater, the ultimate goal was increase naloxone acceptance and availability among the tribal
community. It was felt that giving other staff members, clinical or not, knowledge of the
processes so that they were able to inform others would work towards these larger goals while
supporting the prescribing providers’ more immediate and measurable goals of this project.
The sixth step in Kotter’s model, planning for and creating short-term wins, was achieved
in a number of ways. Throughout the project, administrative support was readily given, thus
facilitating the staff’s acceptance of the change process. Allowing staff and the DNP student
facilitator time to work on the project as a team propelled this intervention forward. The major
win, however, was when organizational leadership approved a direct purchase agreement and
funding for the naloxone to be physically stocked within the clinic. While this additional support
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was not initially anticipated, the DNP student facilitator became aware of this initiative during the
planning stages and incorporated the distribution of stocked naloxone into the implementation
phase. The acquisition of physical naloxone stock eliminated multiple barriers; patients would
be able to receive naloxone without worry of cost, availability, or acquisition. For staff, this early
win was helpful in the anchoring change process, as it created a pathway that would ease and
simplify the procedure of naloxone distribution. Further short-term wins were celebrated by the
occasional delivery of snacks brought by the DNP student facilitator and left in the break areas
for all staff to enjoy, written with a visual message of “Nalox (save some) one: Thanks for all you
do!” This reinforcing strategy also created an opportunity for staff not directly involved with the
project to have conversations regarding naloxone, further contributing to sustained
organizational change and acceptance. Other short-term wins that were directed more
specifically towards the prescribing providers were regular updates at monthly provider
meetings regarding the progress of distribution, such as when the first naloxone had been
dispensed. As was supported in the literature, (Behar et al., 2016; Coffin et al., 2016), a
planned, formalized email was sent at the midway point of the implementation to the prescribing
providers which communicated distribution progress to that point thanking them for their
participation, celebrating the progress to date and providing a reminder to continue with
naloxone co-prescribing practices.
Although Kotter’s model was designed to be linear in nature, the seventh step
(consolidating achievements and producing more change) was recognized both during the
implementation stage and following implementation as data were evaluated. While during the
sixth stage, progress was being communicated for short term wins, this was simultaneously
contributing to the formalized step in the model. At the conclusion of the implementation stage,
all data, results and achievements were translated into a narrative format which describes the
overall effect of the practice change. Furthermore, the results of the EBP project contribute to
anchoring practice change by recognition of future barriers and additional adaptations needed.
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The changes were further anchored during the process of transitioning to a new EHR system,
when the team constructed built in templates for ease of documentation. Additionally, realizing
the distribution process was successful and being utilized by several departments from a single
naloxone stock, funds for the 2018 fiscal year were procured to continue to provide the supply.
Finally, while outside the time constraints of this intervention period, it has been noted during
informal reviews of current naloxone distribution logs that other patients with a documented
chronic opioid medication, have since received naloxone. Most notable is that several of these
patients are male. This is indicative that naloxone co-prescribing practices are continuing to be
adopted by providers and accepted by patients.
The eighth and final step in Kotter’s Change Model is institutionalizing new approaches.
Again, while linear in design, this final step was considered throughout the project in an effort to
not just change naloxone co-prescribing practices for chronic opioid patients, but to change the
naloxone perception and availability for all who utilize the clinic. The team recognized that this
process change was a new approach to safe opioid prescribing and may be uncomfortable for
staff and patients to discuss and accept. Through this EBP project, patients and staff became
more accustomed to naloxone distribution and created a new culture of acceptance and
standard of practice, thus creating a sustainable and viable practice change. To continue
sustainability and anchor organizational change, further efforts have been made to ensure
naloxone stock continues to be accessible to those who utilize it and the DNP student facilitator
continues to act as clinical champion. Additional measures to ease documentation and alert
providers of eligible patients are being built into the new EHR, which will further anchor coprescribing practices. Recognizing that measures to combat the opioid epidemic, whether from
prescribed medications or illicit substances, are rapidly changing, the health department director
and clinical manager continue to support ongoing efforts to stay abreast of the latest trends.
Recently, they have approached the DNP student facilitator, requesting that she attend the May
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2018 National Tribal Public Health Summit and Tribal Health Opioid Consultation, as a
representative of the Clinic X Tribe.
EBP Framework
EBP is model of care driven by evidence-based research, clinical expertise and patient
preference (Schmidt & Brown, 2015). Using these elements, the utilization of EBP improves the
quality and outcomes of patient care. The use of EBP models assists in translating evidence
into clinical practice and provides a systematic approach to navigating complex healthcare
systems and disciplines.
The Iowa Model was chosen for this project as it provides stepwise, team-based
approach to initiating change. The Iowa Model includes (a) identifying a problem-focused or
knowledge-focused trigger, (b) determining if the problem is identified as a priority for the
organization, (c) assembling a team, (d) reviewing and synthesizing the available literature, and
(e) conducting a pilot change (Titler et al., 2001).
Several of the steps with the Iowa Model correlated with Kotter’s 8-Step Process of
Leading Change; thus complementing each other in theory and framework. The Iowa Model
was a good fit because it provided the necessary guidance to initiate the change process. The
five steps of the process were easy to follow and provided the doctoral student guidance and
support for initiating change in a practice that was not engrained with EBP. As the organization
had already made clear that the issue of naloxone distribution was a priority, the first step,
identifying a problem-focused trigger, was easily recognized. Thus, the creation of the team, led
by the doctoral student, was undertaken, and a review of the literature embarked upon. The
Iowa Model directed the team and the DNP student facilitator (in her role of team leader) to
assemble and evaluate evidence that was used to guide implementation of the EBP project.
Upon determining there was sufficient evidence available to proceed with a pilot practice
change, the Iowa Model further guided the DNP student facilitator and team to collect baseline
data, determine outcomes and begin implementation. The pilot change was determined to be

NALOXONE CO-PRESCRIBING

77

successful based on the increase in naloxone co-prescriptions distributed during the
intervention period. Additional review to further improve the EBP practice change has been
discussed in efforts to improve on the current process, with a new outcome objective of
increasing the naloxone co-prescription rate to 75% of all eligible chronic opioid users. The
team initially formed for this project will remain in place and be utilized to translate other EBP
projects into clinical practice changes.
Strengths and Limitations of the EBP Project
Strengths
This EBP project had numerous strengths. The one considered to have the most
impactful effect on the project was the collaboration and cooperation of the leadership and
prescribing providers. The support and desire of the leadership to see this project facilitated
and directed was instrumental in the undertaking and success. The utilization of synthesized
literature to implement evidence-based practice changes was a strength to garner support from
leadership sources. In this project, the health department director and organizational leadership
did not have a clinical background; their area of expertise was business management. Knowing
this, the DNP student facilitator utilized data in terms of significance, costs, and potential longterm savings to further anchor support for the long-term sustainability of this practice change.
Additionally, the collaboration of the prescribing providers, who themselves, while resistant to
changes as most individuals are, recognized that this was an issue which needed to be
addressed. The attention and time devoted by all vested parties proved to be a key
consideration, further aligning with Kotter’s Model of Change and the Iowa Model directive to
determine if an issue is a priority to the organization.
A second strength to this project was the procurement of physical stock and availability
of naloxone. While this was not planned for initially, it was helpful and eliminated barriers
previously noted in similar projects (Behar et al., 2017; Behar et al., 2016; Coffin et al., 2016;
Delaney et al., 2016). It also answered one of the questions initially posed by providers, who
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queried, “even if we write the prescriptions, how do we know they (patients) are filling them?”
The procurement of this stock and initiation of this project also provided an avenue for other
disciplines within the clinic to begin discussions with clients and facilitated the development of a
procedure that enabled staff to dispense kits to those individuals who were felt to benefit from
the receipt of naloxone, whether for themselves or an at-risk family member.
Additionally, this project provided a basis on which to open communication lines
between organizational leadership, the health department, tribal police department and the tribal
affiliated casino security, and emergency medical technician (EMT) staff. Discussion and
implementation of this project, designed to focus on naloxone co-prescribing, sparked further
undertakings to increase naloxone awareness, increase community distribution, and decrease
the negative stigma often associated with naloxone utilization. Through these communications,
the tribal council of the organization has approved future funding for naloxone purchasing, the
tribal police have secured their own stock, and the casino EMTs have had naloxone training and
carry it in their medical bags. The tribal police department has also agreed to the installation of
a secured “Red Med Box” in which unused medications, including opioids, can be safely
disposed. This box had previously sat in the basement of the health department unused and
essentially forgotten, until discussion directly stemming from this project occurred.
Finally, the use of the DNP student facilitator in the role of the clinical champion was
viewed as a strength. While the facilitator was completing the final portion of her doctoral
studies, she was also a practicing NP employed within the organization. This first-hand
knowledge was beneficial to the implementation process and navigation of the organizational
structure unique to tribal entities. The utilization of a prescribing provider colleague in this role
allowed the AD sessions and subsequent contacts with the providers to be tailored to meet the
individual personalities and needs, thus creating further acceptance of a practice change. Time
devoted to leading the change, armed with current knowledge of standard practice within the
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organization, the barriers that may be encountered as well as the expertise and focus for
completion, proved to be instrumental in the successful implementation of this EBP project.
Limitations
While the project had multiple strengths, it certainly was not without limitations. The
major obstacle in the EBP project was the sample size. Having only four prescribing providers
and a small pool of eligible patients (pre-intervention: N = 48, intervention: N = 40) from which to
conduct analyses made it difficult to determine if these results would be replicable on a larger
scale, although they were similar to 25% adoption rates reported in the literature (Devries et al.,
2017), and if the percentage change would be statistically significant if the larger population size
provided adequate power to determine the intervention effect. While the clinical champion was
a nurse practitioner, the providers in the intervention only represented two of the three major
disciplines often seen in primary care, which limits the ability to confidently translate the results
of this EBP project across all education backgrounds. Devries et al. (2017) noted that
physicians (85.3%) were found to be more likely to prescribe naloxone than NPs (9.8%) and
PAs (3.7%), a finding that was replicated similarly in this project (physician prescribing
accounted for 70% of the naloxone co-prescriptions). Consideration of different academic
backgrounds and/or multiple clinical champions may be indicated for future projects of this
design.
Another limitation to this project was being conducted in an organization that while wellversed in grants, QI projects and data collection, was not familiar with formal EBP processes.
Although IRB approval was obtained from the university IRB, the project facility did not have a
formal IRB in place. This was an organization that typically had dissemination through tribal or
governmental channels and was not familiar with the IRB processes which were deemed
necessary by the university to ensure protection of subjects for dissemination of findings. When
the DNP project facilitator approached management and the health department director early in
the process to review the planned intervention and explain the needed approvals, management
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determined that the university IRB approval would be sufficient. A week prior to the planned
intervention start, the health director of the organization began to reconsider whether the
university IRB would be adequate or if a further review process was indicated. The university
IRB packet and approval were given to the health director for review; and, the director
determined that the processes included within the university IRB application were thorough
enough to meet the needs of the tribal organization and permission was obtained to proceed
with the proposed intervention. While ultimately, no delay in the proposed start date occurred,
the timing of the additional review by organizational leadership did result in additional concerns
about being able to carry out the academic detailing sessions as scheduled and determining
whether the project would be conducted at all.
An issue which did delay full implementation status, but ultimately did not appear to
hinder the project outcomes was the availability of the physical naloxone stock. The project was
carefully timed to encompass every three month visit recommendations from the CDC (2016a),
while avoiding the decreased patient volume due to multiple closures related to the approaching
holiday season. As mentioned previously, the availability of the naloxone stock was not part of
the original planned intervention. However, this beneficial procurement was approved and
therefore, incorporated into project. Due to the time constraints of implementation start dates
and availability of the providers, it was deemed prudent to proceed with the scheduled AD
sessions even though the naloxone stock had not arrived at the project facility. The prescribing
providers were instructed to write for a prescription of naloxone, which the patient could then fill
at an off-site pharmacy of their choosing during the interim. Stock arrived ten days after the AD
sessions and was distributed the following day to both project sites by the DNP student
facilitator. Although the DNP student facilitator recognizes that not all clinic facilities attempting
to replicate this EBP project, will be able to supply naloxone directly to the patients, presumably
due to the cost factor, it is noted that no naloxone prescriptions were written when the naloxone
stock was unavailable.
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Another confounding factor that occurred during this project period was the simultaneous
implementation of naloxone distribution by the behavioral health staff, potentially providing
naloxone to mutual patients of the clinic and thus, removing them from data capture. Although
the intention of the project had been made clear to all management staff early in the process,
limited opportunities for communication specifically with the behavioral health manager hindered
collaboration between the departments. This resulted in a separate, parallel intervention
occurring concurrently with the health clinic intervention. While the DNP student facilitator was
able to provide a brief AD session to the behavioral health clinicians, it was not specifically
tailored to their educational background and was limited regarding time allotment. Additionally,
all naloxone was distributed from stock maintained in the clinic via locked access. Although
tracking forms and a process was implemented to track what patients had received naloxone,
this was not seen to fruition with the behavioral health staff. This resulted in a potential loss of
data capture if behavioral health distributed to a shared patient without full documentation on
the tracking logs.
The project facility has faced many challenges with their current EHR and although the
clinical champion worked with the CAC on several initiatives to ease documentation and
educational components regarding naloxone co-prescriptions, this was done with the awareness
that the project facility was changing to a new EHR in the coming fiscal year. While specific
education was given during the provider AD session regarding the process for documentation, it
was found that only one of the naloxone distributions was completed in the EHR and the rest
were tracked solely via the paper distribution log maintained with the naloxone stock. It remains
unclear if the resistance to documentation in the EHR lies with the cumbersome way it must
occur, provider resistance to process change or whether the effort to do so was lacking knowing
that a new documentation system would be implemented in the near future.
Although initially planned to occur more frequently, the clinical champion was limited in
face to face contact. Although the providers were accustomed to practicing in separate clinics,
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there had previously been opportunities for at least monthly in person contact and further video
conferencing contacts. Due to a change in the way monthly health staff meetings were
conducted and the inability to video conference related to equipment issues, the clinical
champion’s ability to have in-person contact was limited. Phone and email contacts were
increased to counteract this issue, however the effect, whether positive or negative, this may
have had on the overall intervention cannot be determined.
Additional limitations that are notable include the rate of patient acceptance. While this
project focused on provider adherence to co-prescribing practices, there was no method
established to determine naloxone acceptance by the patient. Further, there was no formal
tracking method to determine if any of the 40 eligible patients in the project had already received
naloxone from other sources such as community distribution programs. Finally, although the
12-week time frame was chosen to mimic CDC (2016a) recommendations of a re-evaluation
visit, it was also fashioned in that manner to meet the time constraints of the DNP student
facilitators academic schedule. Therefore, it is quite feasible that a longer time frame would
provide increased access to the 40 eligible patients receiving opioids (30 days or greater) and
result in higher naloxone co-prescribing rates.
Implications for the Future
Practice
In response to increasing prevalence and focus on the opioid epidemic, several national
agencies (i.e., the CDC, USDHHS, VHA and IHS) have published guidelines focused on
promoting safe opioid prescribing. Each of these respective guidelines have identified naloxone
co-prescribing as measure to ensure safe prescribing practices, yet the authoring groups have
given little direction on how to accomplish this task.
As clinicians continue to incorporate practice changes to address evolving opioid issues,
this EBP project demonstrates that advanced practice nurses are well situated to search,
evaluate, and appraise rapidly evolving research and develop a systematic approach to
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translate current evidence into daily practice. This project further represents that even when
acting as the lone advanced practice nurse among a multi-disciplinary practice setting, doctoral
prepared nurses are well-positioned to champion the implementation of evidence-based
practice changes. This project can easily be replicated to other tribal health facilities and
primary care settings.
Theory
Change is difficult for many individuals and facilities to embrace. Therefore, a
systematic approach that provides a roadmap to incorporate current evidence and guidance for
overcoming obstacles that may be encountered along the way is crucial when implementing
changes to parties that may be resistant to doing so. Kotter’s Change Model and the Iowa
Model both provided the necessary framework for this project to proceed successfully. Both this
theoretical and EBP framework will continue to be beneficial as the DNP project facilitator
disseminates the results of this project, thus anchoring change in practice and lending support
to future use of these models when implementing additional EBP practice changes.
Research
Future research should include larger sample sizes and multiple clinical facilities to
determine generalization of findings across various settings. Additionally, this EBP project was
conducted over a 12-week implementation time frame and further longitudinal studies are
needed to determine if knowledge garnered from the AD session is sustained or if additional
follow up AD sessions are indicated. Further, the clinical champion in this project was not
available to make face-to-face contact on a frequent basis, therefore additional studies should
evaluate the effectiveness of an off-site versus physically on-site champion and its subsequent
effect on naloxone co-prescribing rates.
While this project facility was able to distribute naloxone at no cost to the patient, this
may be cost prohibitive to other facilities and therefore, not replicable. Additional studies should
be conducted to determine what role, if any, the immediate access plays on provider adoption
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and patient acceptance rates. Finally, this project unfortunately was not designed to evaluate
patient acceptance rates if naloxone was offered. Thus, future research and QI projects should
be designed to evaluate those patients who decline naloxone co-prescribing, the barriers for
acceptance and methodology to decrease those barriers as well as tracking patients who accept
the prescription and whether or not they ultimately obtain the naloxone.
Education
Although patient education was not a targeted objective of this EBP project, it did occur
as an unmeasured component through printed materials and provider – patient discussion. The
AD sessions developed and tailored for the individual prescribing providers were adapted
several times to target additional staff members, who may or may not possess clinical
terminology within their positions. Hence, the DNP facilitator was well situated to morph
between clinical language and lay terminology to meet the needs of the intended audience.
Additionally, this project further opened communication lines for future education and
naloxone distribution, potentially to individuals who did not meet inclusion criteria of this project.
While the prescribing providers, who were the target of this intervention, were supportive and
receptive to naloxone discussions, it became apparent that not all staff members possessed the
same level of comfort and at times were visibly uncomfortable when the conversation was
broached. Future educational efforts should incorporate increased awareness of the
participants’ comfort level regarding naloxone and its use in opioid overdose prevention in order
to best facilitate receptiveness.
Conclusion
This EBP project answered the query posed by the initial PICOT question: Among
primary care providers in a tribal health clinic, does the introduction of an evidence- based multifaceted intervention versus the current practice of no tool, improve the co-prescription rates of
naloxone to chronic opioid patients within a 12- week period? The answer was a resounding
yes. The project further demonstrated that doctoral prepared advanced practice nurses are well

NALOXONE CO-PRESCRIBING

85

situated and adequately educated to act as change agents by the ability to develop, implement
and evaluate clinical practice changes. This a crucial component for improving quality of care
and patient outcomes through the incorporation of evidence-based practices. Additionally, this
project demonstrated that DNP led practice changes can have a positive, unintentional ripple
effect towards larger collaborative organizational changes.
Safe opioid prescribing, and naloxone co-prescribing are a rapidly increasing healthcare
concern which affects people of all genders, ethnicities, ages, geographic locations and
socioeconomical status. Even as this EBP project associated with the DNP student facilitator
coursework comes to a close, the CDC (2018) is releasing new, alarming statistics that the
Midwestern region saw opioid overdose rates increase 70% from July 2016 to September 2017,
the point at which this EBP project intervention began. Experts continue to call for coordinated
efforts among providers to judiciously prescribe opioids and increase naloxone distribution
(CDC, 2018). While this EBP project included small numbers of patients, the findings did
indicate a viable and effective evidenced-based intervention for primary care providers to
contribute to safe opioid prescribing and OEND efforts. Failure to incorporate evidenced-based
practice into efforts to squelch the ever-shifting horizon of the opioid epidemic could result in
devastating consequences to those directly affected and their loved ones left behind.
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APPENDIX A

PERIOD:
MRN#

PRE

GENDER

Male

CHART AUDIT
POST

Female

AGE:
TRIBAL AFFILIATION:
XXX TRIBAL
OTHER TRIBAL
NALOXONE DISPENSED?

SEC. 813
Yes

DOCUMENTED IN EHR? Yes No
CLINIC HOME:

XX

PROVIDER:

XXX
XXX

No
N/A

XX
XXX
XXX

XXX
XXX

Qualifying Med?
Daily MME?
Concurrent Benzo Rx?

Yes

Clinic Visit During Audit Period?
Primary Dx?

No
Yes

No
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Slide 1

___________________________________
Increasing Naloxone Co-Prescription Rates
Among Primary Care Providers: A MultifacetedApproach

___________________________________
___________________________________
___________________________________

Jolane S. Conklin

___________________________________

“I have neither given or received, nor have I tolerated others use of unauthorized aid.”

___________________________________
___________________________________

Slide 2

___________________________________
PICOT

___________________________________

(P)Among primary care providers in a tribal
health clinic,
(I) does the introduction of a multi-faceted
intervention
(C) versus the current practice of no tool
(O) improve the co-prescription rates of
naloxone to chronic opioid patients
(T) in a 3-month period?

___________________________________
___________________________________
___________________________________
___________________________________
___________________________________

Slide 3

___________________________________
Literature Search Process
DATABASE

SEARCH TERMS

LIMITERS

CINAHL

naloxone AND prescri*
AND opioid* OR opiate*
AND primary OR pharm*

PsychINFO

naloxone AND prescri*
AND opioid* OR opiate*
AND primary OR pharm*

Joanna Briggs
Institute
Cochrane

naloxone

2015-2017,
English,
PeerReviewed
2015-2017,
English,
PeerReviewed
2015-2017

MEDLINE (via
EBSCO)
ProQuest

PsychArticles

naloxone AND prescri*
AND opioid* OR opiate*
AND primary OR pharm*
naloxone AND prescri*
AND opioid* OR opiate*
AND primary OR pharm*
naloxone AND prescri*
AND opioid* OR opiate*
AND primary OR pharm*
“naloxone” in abstract
naloxone AND prescri*
AND opioid* OR opiate*
AND primary OR pharm*

Handsearching

naloxone

TOTAL

N/A

2015-2017,
Cochrane
Reviews
2015-2017,
English,
PeerReviewed
2015-2017,
English,
PeerReviewed
2015-2017,
English,
PeerReviewed
2015-2017,
English
N/A

ARTICLES
YIELDED
30

DUPLICATES
0

ABSTRACTS
RIVEWED
11

ARTICLES
USED
2

43

9

11

0

4

0

0

0

5

0

0

0

102

47

12

6

39

9

2

0

0

0

0

0

0

0

0

3

259

65

36

11

___________________________________
___________________________________
___________________________________
___________________________________
___________________________________
___________________________________
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___________________________________

Synthesis of Evidence
Common Themes:
• MAJOR:
– Academic Detailing
– Clinical Champion
– Current Research Rapidly Changing

• MINOR:
– EHR Alerts
– Accessibility of physical naloxone prescription

___________________________________
___________________________________
___________________________________
___________________________________
___________________________________
___________________________________

Slide 5

___________________________________
Objectives:

___________________________________

• Providers/Participants will increase:

___________________________________

– Knowledge base regarding naloxone
– Comfort level of naloxone co-prescribing
– Safer prescribing practices

• Expected Project Outcome:
– Increase in the rate of naloxone coprescriptions

___________________________________
___________________________________
___________________________________
___________________________________

Slide 6

___________________________________
Background Information
• Opioids involved in 61% of all drug overdose
deaths in 2014 (CDC, 2016c)
• Opioid overdoses have quadrupled since 1999
(CDC, 2016c)
• Opioid prescriptions have also quadrupled during
this time frame (CDC, 2016d)

___________________________________
___________________________________
___________________________________
___________________________________
___________________________________
___________________________________
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Slide 7

___________________________________
Background Information – Epidemic Proportions

___________________________________
___________________________________
___________________________________
___________________________________
___________________________________
___________________________________

Slide 8

___________________________________
Since 2009, Drug overdose deaths have
outpaced traffic accidents as the leading cause
of injury death in the United States

___________________________________
___________________________________
___________________________________
___________________________________
___________________________________
___________________________________

Slide 9

___________________________________
• State of Michigan
• Significant Increase between 20142015 (13.3%)
• One of the highest OD death rates
in the nation – 20.4 per 100,000
(Ranked 15th highest)
• Leading Cause of injury death in
Michigan

___________________________________
___________________________________
___________________________________
___________________________________
___________________________________
___________________________________
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___________________________________
___________________________________
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Slide 11

___________________________________
___________________________________
___________________________________
___________________________________
___________________________________
___________________________________
___________________________________
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___________________________________
___________________________________
___________________________________
___________________________________
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___________________________________
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___________________________________

Why NHBP?
• Health needs survey indicated:
– 11.9% of tribal members used RX drug for
experience
– 3.97% admitted misuse of RX drugs in last 30
days (Great Lakes Inter-Tribal Epidemiology Center, 2016)

• ACE Indicators
– 24.23% lived with a problem drinker or alcoholic
before the participant turned 18
– 11.03% lived with someone who abused illegal
street drugs or prescription drugs before the
participant turned 18

___________________________________
___________________________________
___________________________________
___________________________________
___________________________________
___________________________________
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___________________________________
Early Opioid Prescribing Patterns Are Associated With Long
Term Use

___________________________________

• In a March 2017 Study, the Centers for Disease Control Found:
– Even One Prescription for an Opioid Can Be a Trigger For Opioid Abuse

___________________________________

– The Likelihood of Chronic Opioid Use Increases Most Sharply When:
• Patients Are Given a Long-Acting Pain Reliever
• Patients Are Given an initial 10 to 30 Day Supply of Opioids,
• Patients Are Given More than 700 Morphine Milligrams Cumulative
Dose, or

• A Second Prescription or Refill

___________________________________
___________________________________
___________________________________
___________________________________
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___________________________________

Why Naloxone Co-Prescribing?
• Named as a component in several opioid
initiatives
– CDC (2016a) clinical guideline for safe opioid
prescribing
– USDHHS, 2016

• Effective
• Cost-Effective
• “Best-Practice”

___________________________________
___________________________________
___________________________________
___________________________________
___________________________________
___________________________________
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___________________________________
Cost & Benefit
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___________________________________
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___________________________________
Naloxone Pharmacology
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___________________________________
___________________________________
___________________________________
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Slide 20

IHS Naloxone Co-prescribing

___________________________________
___________________________________

•
•
•
•
•
•
•
•
•
•

Recently rotated to a new opioid
Prescribed morphine equivalent daily (MED) dose of 50mg or more
On long-acting opioids particularly if in conjunction with short-acting opioids
Poly-opioid use
Prescribed opioids greater than 30 days
Over the age of 65 years
Households with people at risk of overdose such as children or someone with a substance abuse
disorder
Patients who have difficulty accessing emergency medical services (distance, remoteness, lack of
transportation, homelessness, and/or without phone services)
Recent mandated substance use treatment, incarceration, or period of abstinence with history of drug
abuse
Concurrent prescription or over-the-counter medications
•
•
•
•
•
•

Benzodiazepines
Antipsychotics
Antiepileptics
Muscle relaxers
Hypnotics
Antihistamines

• UNIVERSAL CO-PRESCRIBING????

___________________________________
___________________________________
___________________________________
___________________________________
___________________________________
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___________________________________
Arguments for Universal
Co-Prescribing
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___________________________________
___________________________________
___________________________________
___________________________________
___________________________________
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___________________________________

Opioid Safety Language

___________________________________

• Avoid word “overdose”

___________________________________

– Negative connotations
– Prescription opioid users may not relate

• Instead use:
–
–
–
–

“Accidental overdose”
“Bad Reaction”
“Opioid Safety”
Use Epipen analogy

___________________________________
___________________________________
___________________________________
___________________________________

Slide 23

___________________________________
Other Distribution Notes

___________________________________

• Nasal formulation

___________________________________

– Keep in pack
– Store between 59-77 degrees
– Protect from light

• May provide patient with “Quick Start
Guide” (Included in NHBP policy)
• Opioid Safety pamphlet
• Have patient tell someone where the keep
it!

___________________________________
___________________________________
___________________________________
___________________________________

Slide 24

___________________________________
Documentation

• Able to pick from “Administered in
Clinic” (Thank you Kathie!)

___________________________________
___________________________________
___________________________________
___________________________________

• Document discussion in office note
• Follow NHBP policy

___________________________________
___________________________________
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___________________________________

Current NHBP Policy
•
•
•
•
•
•
•

Copy included in packet
Allows for “3rd Party Prescribing”
Staff mandated to have annual training
Naloxone stored in formulary (or will be)
Adapt pharma training video
Training completion form
Log of distributed naloxone kits

___________________________________
___________________________________
___________________________________
___________________________________
___________________________________
___________________________________

Slide 26

___________________________________
Adapt Pharma Video
• http://adaptpharma.com/newsevents/press-kit/
• Also accessible through “Narcan Now” app
• How would staff like this available for
easier access?
–
–
–
–

Email link?
Install Shortcut to each computer?
Have IT add link to intranet?
Other ideas?

___________________________________
___________________________________
___________________________________
___________________________________
___________________________________
___________________________________
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___________________________________
Michigan Law Updates
•
•
•

•

•

•

Signed into law on Wednesday, Dec. 28, 2016.
Public Act 383 of 2016.
Authority
– This standing order is issued pursuant to Michigan law which
allows the Chief Medical Executive (CME) to issue a standing
order that does not identify particular patients at the time it is
issued, for the purpose of a pharmacist dispensing the opioid
antagonist naloxone. MCL 333.17701 et seq.,
Authorization
– This standing order may be used by pharmacists to generate a
prescription for Eligible Individuals to obtain naloxone from a
pharmacy. This order is authorization for pharmacists to dispense
naloxone and devices for its administration SOLELY in the FDAapproved naloxone formulations and devices prescribed herein.
Link to info regarding law:
http://www.michigan.gov/documents/budget/Emergency_Rules_Opioi
d_Antagonists_572010_7.pdf
http://www.legislature.mi.gov/(S(kxxcot1o5lsyf45ro11bge4c))/mileg.as
px?page=GetObject&objectname=2016-HB-5326

___________________________________
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___________________________________
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What Next?
•
•
•
•
•
•

12 week intervention
Clinical Champion support
MAPS reports for each provider
Article in Fall Health Publication
Other Resources in Packets
Info posters in rooms
– Information for patients
– Visual Reminder for clinic staff

___________________________________
___________________________________
___________________________________
___________________________________
___________________________________
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___________________________________
___________________________________
___________________________________
___________________________________
Questions??

___________________________________
___________________________________
___________________________________
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